Document and Entity Information
Document and Entity Information | 6 Months Ended |
Jun. 30, 2016 | |
Document And Entity Information | |
Entity Registrant Name | OXIS INTERNATIONAL INC |
Entity Central Index Key | 109,657 |
Document Type | S1 |
Document Period End Date | Jun. 30, 2016 |
Amendment Flag | false |
Current Fiscal Year End Date | --12-31 |
Is Entity a Well-known Seasoned Issuer? | No |
Is Entity a Voluntary Filer? | No |
Is Entity's Reporting Status Current? | Yes |
Entity Filer Category | Smaller Reporting Company |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) | Jun. 30, 2016 | Dec. 31, 2015 | Dec. 31, 2014 |
Current Assets: | |||
Cash and cash equivalents | $ 355,000 | $ 47,000 | $ 855,000 |
Prepaid expenses | 2,000 | 2,000 | 27,000 |
Total Current Assets | 357,000 | 49,000 | 882,000 |
Fixed assets, net | 5,000 | 5,000 | 6,000 |
Total Other Assets | 5,000 | 5,000 | 6,000 |
TOTAL ASSETS | 362,000 | 54,000 | 888,000 |
Current Liabilities: | |||
Accounts payable | 1,574,000 | 893,000 | 412,000 |
Accrued interest | 2,853,000 | 2,391,000 | 2,025,000 |
Accrued expenses | 674,000 | 4,326,000 | 3,085,000 |
Line of credit | 31,000 | 31,000 | 28,000 |
Warrant liability | 492,000 | 44,531,000 | 21,581,000 |
Settlement note payable | 691,000 | 691,000 | 691,000 |
Demand notes payable, net of discount of $-0- , $-0- and $-0- | 363,000 | 452,000 | 252,000 |
Convertible debentures, net of discount of $1,952,000, $900,000 and $-0-, current portion | 7,949,000 | 6,820,000 | 1,207,000 |
Convertible debentures | 1,039,000 | 1,039,000 | 547,000 |
Total Current Liabilities | 15,666,000 | 61,174,000 | 29,828,000 |
Long term liabilities: | |||
Convertible debentures, net of discount of $767,000, $2,536,000 and $2,302,000 | 528,000 | 714,000 | 634,000 |
Total long term liabilities | 528,000 | 714,000 | 634,000 |
Total liabilities | 16,194,000 | 61,888,000 | 30,462,000 |
Convertible preferred stock - $0.001 par value; 15,000,000 shares authorized: | |||
Series C - 96,230, 96,230 and 96,230 shares issued and outstanding at June 30, 2016, December 31, 2015 and December 31, 2014, respectively | 1,000 | 1,000 | 1,000 |
Series H - 25,000, 25,000 and 25,000 shares issued and outstanding at June 30, 2016, December 31, 2015 and December 31, 2014, respectively | 0 | 0 | 0 |
Series I - 1,666,667, 1,666,667 and 1,666,667 shares issued and outstanding at June 30, 2016, December 31, 2015 and December 31, 2014, respectively | 2,000 | 2,000 | 2,000 |
Common stock - $0.001 par value; 2,400,000 shares authorized; and 25,889,940, 2,400,000 and 2,366,588 shares issued and outstanding at June 30, 2016, December 31, 2015 and December 31, 2014, respectively | 26,000 | 2,000 | 2,000 |
Additional paid-in capital | 102,498,000 | 84,012,000 | 83,546,000 |
Accumulated deficit | (118,190,000) | (145,682,000) | (112,956,000) |
Noncontrolling interest | (169,000) | (169,000) | (169,000) |
Total Stockholders' Deficit | (15,832,000) | (61,834,000) | (29,574,000) |
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT | $ 362,000 | $ 54,000 | $ 888,000 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - USD ($) | Jun. 30, 2016 | Dec. 31, 2015 | Dec. 31, 2014 |
Current Liabilities: | |||
Convertible debentures, discount | $ 1,952,000 | $ 900,000 | $ 0 |
Demand notes payable, discount | $ 0 | $ 0 | $ 0 |
Stockholders' Deficit: | |||
Preferred stock, par value | $ 0.001 | $ 0.001 | $ 0.001 |
Preferred stock, Authorized | 15,000,000 | 15,000,000 | 15,000,000 |
Series C - Preferred stock, issued shares | 96,230 | 96,230 | 96,230 |
Series C - Preferred stock, outstanding shares | 96,230 | 96,230 | 96,230 |
Series H - Preferred stock, issued shares | 25,000 | 25,000 | 25,000 |
Series H - Preferred stock, outstanding shares | 25,000 | 25,000 | 25,000 |
Series I - Preferred stock, issued shares | 1,666,667 | 1,666,667 | 1,666,667 |
Series I - Preferred stock, outstanding shares | 1,666,667 | 1,666,667 | 1,666,667 |
Common stock, par value | $ 0.001 | $ 0.001 | $ 0.001 |
Common stock, Authorized | 150,000,000 | 2,400,000 | 2,400,000 |
Common stock, Issued | 25,889,940 | 2,400,000 | 2,366,588 |
Common stock, outstanding | 25,889,940 | 2,400,000 | 2,366,588 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2016 | Jun. 30, 2015 | Jun. 30, 2016 | Jun. 30, 2015 | Dec. 31, 2015 | Dec. 31, 2014 | |
Revenue: | ||||||
Product revenues | $ 0 | $ 0 | $ 0 | $ 0 | $ 0 | $ 28,000 |
License revenues | 0 | 20,000 | 0 | 27,000 | 27,000 | 33,000 |
TOTAL NET REVENUE | 0 | 20,000 | 0 | 27,000 | 27,000 | 61,000 |
Cost of Product Revenue | 0 | 0 | 0 | 0 | 0 | 57,000 |
Gross profit | 0 | 20,000 | 0 | 27,000 | 27,000 | 4,000 |
Operating Expenses: | ||||||
Research and development | 250,000 | 0 | 475,000 | 250,000 | 1,000,000 | 0 |
Selling, general and administrative | 1,871,000 | 1,451,000 | 5,547,000 | 3,019,000 | 7,954,000 | 2,400,000 |
Total operating expenses | 2,121,000 | 1,451,000 | 6,022,000 | 3,269,000 | 8,954,000 | 2,400,000 |
Loss from Operations | (2,121,000) | (1,431,000) | (6,022,000) | (3,242,000) | (8,927,000) | (2,396,000) |
Other income (expense) | ||||||
Change in value of warrant and derivative liabilities | 5,263,000 | 29,140,000 | 36,759,000 | 17,874,000 | (6,760,000) | (15,963,000) |
Interest expense/income | (1,599,000) | (849,000) | (3,245,000) | (8,288,000) | (17,039,000) | (5,146,000) |
Total Other Income (Expense) | 3,664,000 | 28,291,000 | 33,514,000 | 9,586,000 | (23,799,000) | (21,109,000) |
Income (Loss) before minority interest and provision for income taxes | 1,543,000 | 26,860,000 | 27,492,000 | 6,344,000 | (32,726,000) | (23,505,000) |
Plus: net (income) loss attributable to the noncontrolling interests | 0 | 0 | 0 | 0 | 0 | 16,000 |
Income (Loss) before provision for income taxes | 1,543,000 | 26,860,000 | 27,492,000 | 6,344,000 | (32,726,000) | (23,489,000) |
Provision for income taxes | 0 | 0 | 0 | 0 | 0 | 0 |
Net income (loss) | $ 1,543,000 | $ 26,860,000 | $ 27,492,000 | $ 6,344,000 | $ (32,726,000) | $ (23,489,000) |
Income/(loss) per share - Basic | $ 0.07 | $ 11.21 | $ 1.35 | $ 2.66 | ||
Income/(loss) per share - Diluted | $ 0.06 | $ 5.47 | $ 1.22 | $ 1.29 | ||
Loss Per Share - basic and diluted | $ (13.67) | $ (0.04) | ||||
Weighted Average Common Shares Outstanding - Basic | 23,335,603 | 2,396,381 | 20,375,396 | 2,389,080 | ||
Weighted Average Common Shares Outstanding - Diluted | 25,407,055 | 4,907,238 | 22,446,848 | 4,899,898 | ||
Weighted Average Shares Outstanding - Basic and diluted | 2,394,540 | 2,327,873 |
Consolidated Statement of Stock
Consolidated Statement of Stockholders' Deficit - USD ($) | Preferred Stock | Common Stock | Additional Paid-In Capital | Accumulated Deficit |
Beginning Balance, Shares at Dec. 31, 2013 | 1,787,897 | 2,291,936 | ||
Beginning Balance, Amount at Dec. 31, 2013 | $ 3,000 | $ 2,000 | $ 83,281,000 | $ (89,467,000) |
Issuance of stock options | 162,000 | |||
Issuance of common stock for accrued expenses, shares | 74,652 | |||
Issuance of common stock for accrued expenses, amount | 103,000 | |||
Net loss | (23,489,000) | |||
Ending Balance, Shares at Dec. 31, 2014 | 1,787,897 | 2,366,588 | ||
Ending Balance, Amount at Dec. 31, 2014 | $ 3,000 | $ 2,000 | 83,546,000 | (112,956,000) |
Issuance of stock options | 220,000 | |||
Issuance of common stock for accrued expenses, shares | 33,412 | |||
Issuance of common stock for accrued expenses, amount | 246,000 | |||
Net loss | (32,726,000) | |||
Ending Balance, Shares at Dec. 31, 2015 | 1,787,897 | 2,400,000 | ||
Ending Balance, Amount at Dec. 31, 2015 | $ 3,000 | $ 2,000 | $ 84,012,000 | $ (145,682,000) |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2016 | Jun. 30, 2015 | Dec. 31, 2015 | Dec. 31, 2014 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||
Net income (loss) | $ 27,492,000 | $ 6,344,000 | $ (32,726,000) | $ (23,489,000) |
Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||||
Depreciation | 0 | 1,000 | 2,000 | 0 |
Amortization of intangible assets | 0 | 0 | 0 | 22,000 |
Stock compensation expense for options and warrants issued to employees and non-employees | 4,051,000 | 231,000 | 3,761,000 | 2,630,000 |
Note Allonges | 3,667,000 | 0 | ||
Amortization of debt discounts | 972,000 | 1,043,000 | 2,494,000 | 2,759,000 |
Non-cash interest expense | 1,504,000 | 6,880,000 | 9,840,000 | 2,764,000 |
Change in value of warrant and derivative liabilities | (36,759,000) | (17,874,000) | 7,400,000 | 13,962,000 |
Note Settlement | 0 | (176,000) | ||
Changes in operating assets and liabilities: | ||||
Accounts receivable | 0 | 0 | ||
Inventory | 0 | 42,000 | ||
Other assets | 0 | 25,000 | 25,000 | 13,000 |
Accounts payable and accrued expenses | 1,508,000 | 270,000 | 880,000 | (276,000) |
Net cash used in operating activities | (1,232,000) | (3,080,000) | (4,657,000) | (1,749,000) |
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||
Acquisition of fixed assets | (1,000) | (6,000) | ||
Net cash used by investing activities | (1,000) | (6,000) | ||
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||
Proceeds from notes payable | 1,540,000 | 2,350,000 | 3,850,000 | 2,589,000 |
Repayment of note payable | 0 | 0 | 0 | (6,000) |
Net cash provided by financing activities | 1,540,000 | 2,350,000 | 3,850,000 | 2,583,000 |
Minority Interest | 0 | 0 | 0 | (16,000) |
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | 308,000 | (730,000) | (808,000) | 812,000 |
CASH AND CASH EQUIVALENTS - Beginning of period | 47,000 | 855,000 | 855,000 | 43,000 |
CASH AND CASH EQUIVALENTS - End of period | 355,000 | 125,000 | $ 47,000 | $ 855,000 |
Supplemental Disclosures: | ||||
Interest paid | 0 | 0 | ||
Income taxes paid | 0 | 0 | ||
Supplemental non-cash activities | ||||
Issuance of common stock for interest expense | 0 | 247,000 | ||
Issuance of common stock to convert notes payable | 1,429,000 | 0 | ||
Issuance of common stock in payment of accrued interest | $ 270,000 | $ 0 |
Note 1 - The Company and Summar
Note 1 - The Company and Summary of Significant Accounting Policies | 6 Months Ended | 12 Months Ended |
Jun. 30, 2016 | Dec. 31, 2015 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Note 1 - The Company and Summary of Significant Accounting Policies | OXIS International, Inc. (collectively, OXIS or the Company) is engaged in discovering, developing and commercializing novel therapeutics from our proprietary product platform in a broad range of disease areas. Currently, OXIS develops innovative drugs focused on the treatment of cancer. OXIS' lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer. In in vitro in vivo in vitro in vivo In 1965, the corporate predecessor of OXIS, Diagnostic Data, Inc. was incorporated in the State of California. Diagnostic Data changed its incorporation to the State of Delaware in 1972; and changed its name to DDI Pharmaceuticals, Inc. in 1985. In 1994, DDI Pharmaceuticals merged with International BioClinical, Inc. and Bioxytech S.A. and changed its name to OXIS International, Inc. Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP) and the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Certain information and disclosures required by U.S. GAAP for complete consolidated financial statements have been condensed or omitted herein. The interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Form 10-K for the year ended December 31, 2015. The unaudited interim condensed consolidated financial information presented herein reflects all normal adjustments that are, in the opinion of management, necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. The Company is responsible for the unaudited interim consolidated financial statements included in this report. The results of operations of any interim period are not necessarily indicative of the results for the full year. Going Concern As shown in the accompanying consolidated financial statements, the Company has incurred an accumulated deficit of $118,190,000 through June 30, 2016. On a consolidated basis, the Company had cash and cash equivalents of $355,000 at June 30, 2016. The Company's plan is to raise additional capital until such time that the Company generates sufficient revenues to cover its cash flow needs and/or it achieves profitability. However, the Company cannot assure that it will accomplish this task and there are many factors that may prevent the Company from reaching its goal of profitability. The current rate of cash usage raises substantial doubt about the Companys ability to continue as a going concern, absent any sources of significant cash flows. In an effort to mitigate this near-term concern the Company intends to seek additional equity or debt financing to obtain sufficient funds to sustain operations. However, the Company cannot provide assurance that it will successfully obtain equity or debt or other financing, if any, sufficient to finance its goals or that the Company will generate future product related revenues. The Companys financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue in existence. Basis of Consolidation and Comprehensive Income The accompanying consolidated financial statements include the accounts of OXIS International, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated. The Company's financial statements are prepared using the accrual method of accounting. Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. Concentrations of Credit Risk The Company's cash and cash equivalents, marketable securities and accounts receivable are monitored for exposure to concentrations of credit risk. The Company maintains substantially all of its cash balances in a limited number of financial institutions. The balances are each insured by the Federal Deposit Insurance Corporation up to $250,000. The Company does not have balances in excess of this limit at June 30, 2016. Fair Value of Financial Instruments The carrying amounts of cash and cash equivalents, restricted cash, accounts receivable, inventory, accounts payable and accrued expenses approximate fair value because of the short-term nature of these instruments. The fair value of debt is based upon current interest rates for debt instruments with comparable maturities and characteristics and approximates the carrying amount. Stock Based Compensation to Other than Employees The Company accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance with ASC 718. Costs are measured at the estimated fair market value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably determinable. The value of equity instruments issued for consideration other than employee services is determined on the earlier of a performance commitment or completion of performance by the provider of goods or services. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized over the term of the consulting agreement. Impairment of Long Lived Assets The Company's long-lived assets currently consist of capitalized patents. The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. If any of the Company's long-lived assets are considered to be impaired, the amount of impairment to be recognized is equal to the excess of the carrying amount of the assets over the fair value of the assets. Income Taxes The Company accounts for income taxes using the asset and liability approach, whereby deferred income tax assets and liabilities are recognized for the estimated future tax effects, based on current enacted tax laws, of temporary differences between financial and tax reporting for current and prior periods. Deferred tax assets are reduced, if necessary, by a valuation allowance if the corresponding future tax benefits may not be realized. Net Income (Loss) per Share Basic net income (loss) per share is computed by dividing the net loss for the period by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing the net loss for the period by the weighted average number of common shares outstanding during the period, plus the potential dilutive effect of common shares issuable upon exercise or conversion of outstanding stock options and warrants during the period. The weighted average number of potentially dilutive common shares excluded from the calculation of net income (loss) per share totaled in 12,900,521 and 1,677,144 as of June 30, 2016 and 2015, respectively. Patents Acquired patents are capitalized at their acquisition cost or fair value. The legal costs, patent registration fees and models and drawings required for filing patent applications are capitalized if they relate to commercially viable technologies. Commercially viable technologies are those technologies that are projected to generate future positive cash flows in the near term. Legal costs associated with patent applications that are not determined to be commercially viable are expensed as incurred. All research and development costs incurred in developing the patentable idea are expensed as incurred. Legal fees from the costs incurred in successful defense to the extent of an evident increase in the value of the patents are capitalized. Capitalized cost for pending patents are amortized on a straight-line basis over the remaining twenty year legal life of each patent after the costs have been incurred. Once each patent is issued, capitalized costs are amortized on a straight-line basis over the shorter of the patent's remaining statutory life, estimated economic life or ten years. Fixed Assets Fixed assets are stated at cost. Depreciation is computed on a straight-line basis over the estimated useful lives of the assets, which are 3 to 10 years for machinery and equipment and the shorter of the lease term or estimated economic life for leasehold improvements. Fair Value The carrying amounts reported in the balance sheets for receivables and current liabilities each qualify as financial instruments and are a reasonable estimate of fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest. The three levels are defined as follows: ● Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. The Companys Level 1 assets include cash equivalents, primarily institutional money market funds, whose carrying value represents fair value because of their short-term maturities of the investments held by these funds. ● Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. The Companys Level 2 liabilities consist of liabilities arising from the issuance of convertible securities and in accordance with ASC 815-40: a warrant liability for detachable warrants, as well as an accrued derivative liability for the beneficial conversion feature. These liabilities are remeasured each reporting period. Fair value is determined using the Black-Scholes valuation model based on observable market inputs, such as share price data and a discount rate consistent with that of a government-issued security of a similar maturity. ● Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement. The following table represents the Companys assets and liabilities by level measured at fair value on a recurring basis at June 30, 2016. Description Level 1 Level 2 Level 3 Assets $ $ $ Liabilities Warrant liability 492,000 Research and Development Research and development costs are expensed as incurred and reported as research and development expense. Research and development costs totaling $475,000 and $250,000 for the six months ended June 30, 2016 and 2015, respectively. Revenue Recognition License Revenue License arrangements may consist of non-refundable upfront license fees, exclusive licensed rights to patented or patent pending technology, and various performance or sales milestones and future product royalty payments. Some of these arrangements are multiple element arrangements. Non-refundable, up-front fees that are not contingent on any future performance by us, and require no consequential continuing involvement on our part, are recognized as revenue when the license term commences and the licensed data, technology and/or compound is delivered. We defer recognition of non-refundable upfront fees if we have continuing performance obligations without which the technology, right, product or service conveyed in conjunction with the non-refundable fee has no utility to the licensee that is separate and independent of our performance under the other elements of the arrangement. In addition, if we have continuing involvement through research and development services that are required because our know-how and expertise related to the technology is proprietary to us, or can only be performed by us, then such up-front fees are deferred and recognized over the period of continuing involvement. Payments related to substantive, performance-based milestones in a research and development arrangement are recognized as revenue upon the achievement of the milestones as specified in the underlying agreements when they represent the culmination of the earnings process. Use of Estimates The financial statements and notes are representations of the Company's management, which is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities revenues and expenses and disclosures of contingent assets and liabilities at the date of the financial statements. Actual results could differ from those estimates. | OXIS International, Inc. (collectively, OXIS or the Company) is engaged in discovering, developing and commercializing novel therapeutics from our proprietary product platform in a broad range of disease areas. Currently, OXIS develops innovative drugs focused on the treatment of cancer. OXIS' lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer. In in vitro in vivo in vitro in vivo In 1965, the corporate predecessor of OXIS, Diagnostic Data, Inc. was incorporated in the State of California. Diagnostic Data changed its incorporation to the State of Delaware in 1972; and changed its name to DDI Pharmaceuticals, Inc. in 1985. In 1994, DDI Pharmaceuticals merged with International BioClinical, Inc. and Bioxytech S.A. and changed its name to OXIS International, Inc. Going Concern As shown in the accompanying consolidated financial statements, the Company has incurred an accumulated deficit of $145,682,000 through December 31, 2015. On a consolidated basis, the Company had cash and cash equivalents of $47,000 at December 31, 2015. The Company's plan is to raise additional capital until such time that the Company generates sufficient revenues to cover its cash flow needs and/or it achieves profitability. However, the Company cannot assure that it will accomplish this task and there are many factors that may prevent the Company from reaching its goal of profitability. The current rate of cash usage raises substantial doubt about the Companys ability to continue as a going concern, absent any sources of significant cash flows. In an effort to mitigate this near-term concern the Company intends to seek additional equity or debt financing to obtain sufficient funds to sustain operations. The Company plans to increase revenues by introducing new nutraceutical products primarily based on its ergothioneine assets. However, the Company cannot provide assurance that it will successfully obtain equity or debt or other financing, if any, sufficient to finance its goals or that the Company will generate future product related revenues. The Companys financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue in existence. Accounts receivable The Company carries its accounts receivable at cost less an allowance for doubtful accounts. On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance for doubtful accounts, based on a history of past write-offs and collections and current credit conditions. Advertising and promotional fees Advertising expenses consist primarily of costs incurred in the design, development, and printing of Company literature and marketing materials. The Company expenses all advertising expenditures as incurred. There were no advertising expenses for the years ended December 31, 2015 and 2014, respectively. Basis of Consolidation and Comprehensive Income The accompanying consolidated financial statements include the accounts of OXIS International, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated. The Company's financial statements are prepared using the accrual method of accounting. Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. Concentrations of Credit Risk The Company's cash and cash equivalents, marketable securities and accounts receivable are monitored for exposure to concentrations of credit risk. The Company maintains substantially all of its cash balances in a limited number of financial institutions. The balances are each insured by the Federal Deposit Insurance Corporation up to $250,000. The Company does not have balances in excess of this limit at December 31, 2015. Fair Value of Financial Instruments The carrying amounts of cash and cash equivalents, restricted cash, accounts receivable, inventory, accounts payable and accrued expenses approximate fair value because of the short-term nature of these instruments. The fair value of debt is based upon current interest rates for debt instruments with comparable maturities and characteristics and approximates the carrying amount. Stock Based Compensation to Employees The Company accounts for its stock-based compensation for employees in accordance with Accounting Standards Codification (ASC) 718. The Company recognizes in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees and non-employees over the related vesting period. The Company granted stock options to purchase 52,000 and 321,833 shares of the Companys common stock to employees and directors during the year ended December 31, 2015 and 2014, respectively. The fair values of employee stock options are estimated for the calculation of the pro forma adjustments at the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions during 2015: expected volatility of 90%; average risk-free interest rate of 1.50% initial expected life of 5 years; no expected dividend yield; and amortized over the vesting period of typically one to four years. The Company reported an expense for share-based compensation for its employees and directors of $221,000 and $162,000 for the year ended December 31, 2015 and 2014, respectively. Impairment of Long Lived Assets The Company's long-lived assets currently consist of capitalized patents The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. If any of the Company's long-lived assets are considered to be impaired, the amount of impairment to be recognized is equal to the excess of the carrying amount of the assets over the fair value of the assets. Income Taxes The Company accounts for income taxes using the asset and liability approach, whereby deferred income tax assets and liabilities are recognized for the estimated future tax effects, based on current enacted tax laws, of temporary differences between financial and tax reporting for current and prior periods. Deferred tax assets are reduced, if necessary, by a valuation allowance if the corresponding future tax benefits may not be realized. Net Income (Loss) per Share Basic net income (loss) per share is computed by dividing the net loss for the period by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing the net loss for the period by the weighted average number of common shares outstanding during the period, plus the potential dilutive effect of common shares issuable upon exercise or conversion of outstanding stock options and warrants during the period. The weighted average number of potentially dilutive common shares excluded from the calculation of net income (loss) per share totaled in 12,525,721 in 2015 and 3,092,737 in 2014. Patents Acquired patents are capitalized at their acquisition cost or fair value. The legal costs, patent registration fees and models and drawings required for filing patent applications are capitalized if they relate to commercially viable technologies. Commercially viable technologies are those technologies that are projected to generate future positive cash flows in the near term. Legal costs associated with patent applications that are not determined to be commercially viable are expensed as incurred. All research and development costs incurred in developing the patentable idea are expensed as incurred. Legal fees from the costs incurred in successful defense to the extent of an evident increase in the value of the patents are capitalized. Capitalized cost for pending patents are amortized on a straight-line basis over the remaining twenty year legal life of each patent after the costs have been incurred. Once each patent is issued, capitalized costs are amortized on a straight-line basis over the shorter of the patent's remaining statutory life, estimated economic life or ten years. Fixed Assets Fixed assets is stated at cost. Depreciation is computed on a straight-line basis over the estimated useful lives of the assets, which are 3 to 10 years for machinery and equipment and the shorter of the lease term or estimated economic life for leasehold improvements. Fair Value The carrying amounts reported in the balance sheets for receivables and current liabilities each qualify as financial instruments and are a reasonable estimate of fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest. The three levels are defined as follows: · Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. The Companys Level 1 assets include cash equivalents, primarily institutional money market funds, whose carrying value represents fair value because of their short-term maturities of the investments held by these funds. · Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. The Companys Level 2 liabilities consist of liabilities arising from the issuance of convertible securities and in accordance with ASC 815-40: a warrant liability for detachable warrants, as well as an accrued derivative liability for the beneficial conversion feature. These liabilities are remeasured each reporting period. Fair value is determined using the Black-Scholes valuation model based on observable market inputs, such as share price data and a discount rate consistent with that of a government-issued security of a similar maturity. · Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement. The following table represents the Companys assets and liabilities by level measured at fair value on a recurring basis at December 31, 2015. Description Level 1 Level 2 Level 3 Assets $ $ $ Liabilities Warrant liability 44,531,000 Accrued expense 4,326,000 Research and Development Research and development costs are expensed as incurred and reported as research and development expense. Research and development costs totaling $1,000,000 and $-0- for the years ended December 31, 2015 and 2014, respectively. Revenue Recognition Product Revenue The Company manufactures, or has manufactured on a contract basis, fine chemicals and nutraceutical products, which are its primary products to be sold to customers. Revenue from the sale of its products, including shipping fees, will be recognized when title to the products is transferred to the customer which usually occurs upon shipment or delivery, depending upon the terms of the sales order and when collectability is reasonably assured. Revenue from sales to distributors of its products will be recognized, net of allowances, upon delivery of product to the distributors. According to the terms of individual distributor contracts, a distributor may return product up to a maximum amount and under certain conditions contained in its contract. Allowances are calculated based upon historical data, current economic conditions and the underlying contractual terms. License Revenue License arrangements may consist of non-refundable upfront license fees, exclusive licensed rights to patented or patent pending technology, and various performance or sales milestones and future product royalty payments. Some of these arrangements are multiple element arrangements. Non-refundable, up-front fees that are not contingent on any future performance by us, and require no consequential continuing involvement on our part, are recognized as revenue when the license term commences and the licensed data, technology and/or compound is delivered. We defer recognition of non-refundable upfront fees if we have continuing performance obligations without which the technology, right, product or service conveyed in conjunction with the non-refundable fee has no utility to the licensee that is separate and independent of our performance under the other elements of the arrangement. In addition, if we have continuing involvement through research and development services that are required because our know-how and expertise related to the technology is proprietary to us, or can only be performed by us, then such up-front fees are deferred and recognized over the period of continuing involvement. Payments related to substantive, performance-based milestones in a research and development arrangement are recognized as revenue upon the achievement of the milestones as specified in the underlying agreements when they represent the culmination of the earnings process. Use of Estimates The financial statements and notes are representations of the Company's management, which is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities revenues and expenses and disclosures of contingent assets and liabilities at the date of the financial statements. Actual results could differ from those estimates. |
Note 2 - Patents
Note 2 - Patents | 12 Months Ended |
Dec. 31, 2015 | |
Notes to Financial Statements | |
Note 2 - Patents | December 31, 2015 December 31, 2014 Capitalized patent costs $ 642,000 $ 642,000 Accumulated amortization (642,000 ) (642,000 ) $ - $ - Periodically, the Company reviews its patent portfolio and has determined that certain patent applications no longer possessed commercial viability or were abandoned since they were inconsistent with the Company's business development strategy. |
Note 3 - Debt
Note 3 - Debt | 6 Months Ended | 12 Months Ended |
Jun. 30, 2016 | Dec. 31, 2015 | |
Debt Disclosure [Abstract] | ||
Note 3 - Debt | Convertible debentures On October 25, 2006, the Company entered into a securities purchase agreement (2006 Purchase Agreement) with four accredited investors (the 2006 Purchasers). In conjunction with the signing of the 2006 Purchase Agreement, the Company issued secured convertible debentures (2006 Debentures) and Series A, B, C, D, and E common stock warrants (2006 Warrants) to the 2006 Purchasers, and the parties also entered into a security agreement (the 2006 Security Agreement) pursuant to which the Company agreed to grant the 2006 Purchasers, pari passu, a security interest in substantially all of the Companys assets. Pursuant to the terms of the 2006 Purchase Agreement, the Company issued the 2006 Debentures in an aggregate principal amount of $1,694,250 to the 2006 Purchasers. The 2006 Debentures are subject to an original issue discount of 20.318% resulting in proceeds to the Company of $1,350,000 from the transaction. The 2006 Debentures were due on October 25, 2008. The 2006 Debentures are convertible, at the option of the 2006 Purchasers, at any time prior to payment in full, into shares of common stock of the Company. As a result of the full ratchet anti-dilution provision the current conversion price is $2.50 per share (the 2006 Conversion Price). Beginning on the first of the month beginning February 1, 2007, the Company was required to amortize the 2006 Debentures in equal installments on a monthly basis resulting in a complete repayment by the maturity date (the Monthly Redemption Amounts). The Monthly Redemption Amounts could have been paid in cash or in shares, subject to certain restrictions. If the Company chose to make any Monthly Redemption Amount payment in shares of common stock, the price per share would have been the lesser of the Conversion Price then in effect and 85% of the weighted average price for the 10-trading days prior to the due date of the Monthly Redemption Amount. The Company did not make any of the required monthly redemption payments. Pursuant to the provisions of the 2006 Debentures, such non-payment was an event of default and penalty interest has accrued on the unpaid redemption balance at an interest rate equal to the lower of 18% per annum and the maximum rate permitted by applicable law. In addition, each of the 2006 Purchasers has the right to accelerate the cash repayment of at least 130% of the outstanding principal amount of the 2006 Debenture (plus accrued but unpaid liquidated damages and interest) and to sell substantially all of the Companys assets pursuant to the provisions of the 2006 Security Agreement to satisfy any such unpaid balance. On June 6, 2008, the Company received notification from Bristol Investment Fund, Ltd (Bristol), that the collateral held under the 2006 Security Agreement would be sold to the highest qualified bidder on Thursday, June 19, 2008. On June 19, 2008, the Company received a Notice of Disposition of Collateral from Bristol in which Bristol notified the Company that Bristol, acting as the agent for itself and the three other 2006 Purchasers, purchased certain assets held as collateral under the 2006 Security Agreement. Bristol purchased 111,025 shares of common stock of BioCheck, Inc., the Companys majority owned subsidiary, on a credit bid of $50,000, and Bristol also purchased 1,000 shares of the capital stock of OXIS Therapeutics, Inc., a wholly owned subsidiary of OXIS, for a credit bid of $10,000. In December 2005, OXIS purchased the 111,025 shares of common stock of BioCheck, Inc. for $3,060,000. After crediting the aggregate amount of $60,000 to the aggregate amount due under the 2006 Debentures, plus fees and charges due through June 19, 2008, Bristol notified the Company that the Company remains obligated to the 2006 Purchasers in a deficiency in an aggregate amount of $2,688,000 as of June 19, 2008. As a result of the disposition of the collateral, the Company recorded a net loss aggregating $2,978,000. Under the 2006 Purchase Agreement, the 2006 Purchasers also have a right of first refusal to participate in up to 100% of any future financing undertaken by the Company until the 2006 Debentures are no longer outstanding. In addition, the Company is also prohibited from effecting any subsequent financing involving a variable rate transaction until such time as no 2006 Purchaser holds any of the 2006 Debentures. Furthermore, so long as any 2006 Purchaser holds any of the securities issued under the 2006 Purchase Agreement, if the Company issues or sells any common stock or instruments convertible into common stock which a 2006 Purchaser reasonably believes is on terms more favorable to such investors than the terms pursuant to the 2006 Debentures or 2006 Warrants, the Company is obligated to permit such 2006 Purchaser the benefits of such better terms. Of the 2006 Warrants issued by the Company to the 2006 Purchasers, only the Series A Warrants remain outstanding. The Series A Warrants, which now expire in July 2019, permit the holders to purchase 9,681 shares of common stock at an original exercise price of $87.50 per share. Such exercise price is adjustable pursuant to a full ratchet anti-dilution provision and upon the occurrence of a stock split or a related event. During 2009, Bristol converted $177,900 of the principal amount of 2006 Debentures for 71,160 shares of the Companys common stock. During 2010, Bristol converted an additional $401,000 of the principal amount of 2006 Debentures for 160,400 shares of the Companys common stock. During 2011, an additional $605,000 of the principal amount of 2006 Debentures was converted into 242,000 shares of the Companys common stock. During 2012, an additional $369,625 of the principal amount of 2006 Debentures was converted into 350,619 shares of the Companys common stock. The 2006 Debentures do not meet the definition of a conventional convertible debt instrument since they are not convertible into a fixed number of shares. The Monthly Redemption Amounts can be paid with common stock at a conversion price that is a percentage of the market price; therefore the number of shares that could be required to be delivered upon net-share settlement is essentially indeterminate. Therefore, the 2006 Debentures are considered non-conventional, which means that the conversion feature must be bifurcated from the debt and shown as a separate derivative liability. This beneficial conversion liability has been calculated to be $690,000 on October 25, 2006. In addition, since the 2006 Debentures are convertible into an indeterminate number of shares of common stock, it is assumed that the Company could never have enough authorized and unissued shares to settle the conversion of the 2006 Warrants issues in this transaction into common stock. Therefore, the 2006 Warrants have a fair value of $2,334,000 at October 25, 2006. The value of the 2006 Warrant was calculated using the Black-Scholes model using the following assumptions: Discount rate of 4.5%, volatility of 158% and expected term of 1 to 6 years. The fair value of the beneficial conversion feature and the 2006 Warrant liability will be adjusted to fair value on each balance sheet date with the change being shown as a component of net loss. The fair value of the beneficial conversion feature and the 2006 Warrants at the inception of the 2006 Debentures were $690,000 and $2,334,000, respectively. The first $1,350,000 of these discounts was amortized over the term of the 2006 Debenture and the excess of $1,674,000 was shown as financing costs in statement of operations. The Company and Bristol entered into a Forbearance Agreement on December 3, 2015, pursuant to which Bristol agreed to refrain and forbear from exercising certain rights and remedies with respect the 2006 Debentures for three months. In exchange for the Forbearance Agreement, the Company issued an allonge in the amount of $250,000 increasing the principal amount if the 2006 Debentures. On October 1, 2009, the Company entered into a financing arrangement with several accredited investors (the 2009 Investors), pursuant to which it sold various securities in consideration of a maximum aggregate purchase price of $2,000,000 (the 2009 Financing). In connection with the 2009 Financing, the Company issued the following securities to the 2009 Investors: ● 0% Convertible Debentures in the principal amount of $2,000,000 due 24 months from the date of issuance (the 2009 Debentures), convertible into shares of the Companys common stock at a per share conversion price equal to $12.50 per share; ● Series A warrant to purchase such number of shares of the Companys common stock equal to 50% of the principal amount invested by each 2009 Investor (the 2009 Class A Warrants ) resulting in the issuance of Class A Warrants to purchase 80,000 shares of common stock of the Company. ● Series B warrant to purchase such number of shares of the Companys common stock equal to 50% of the principal amount invested by each 2009 Investor (the 2009 Class B Warrants) resulting in the issuance of Class B Warrants to purchase 80,000 shares of common stock of the Company. The Class A Warrants and Class B Warrants (collectively, the 2009 Warrants) are exercisable for up to five years from the date of issue at a per share exercise price equal to $15.625 and $18.75 for the Class A Warrants and the Class B Warrants, respectively, on a cash or cashless basis. The 2009 Debentures and the 2009 Warrants are collectively referred to herein as the 2009 Securities. In connection with the sale of the 2009 Securities by the Company, the Company and Bristol entered a Standstill and Forbearance Agreement, pursuant to which Bristol agreed to refrain and forbear from exercising certain rights and remedies with respect to (i) the 2006 Debentures and (ii) certain demand notes (the Bridge Notes) issued by the Company on October 8, 2008, March 19, 2009, April 7, 2009, April 28, 2009, May 21, 2009 and June 25, 2009 and discussed under the caption Demand Notes below. In connection with the sale of the 2009 Securities by the Company, the Company and Bristol have also entered into a waiver agreement (the Waiver Agreement) pursuant to which Bristol waived certain rights with respect to the 2006 Debentures and Bridge Notes. The conversion price of the 2009 Debentures and the exercise price of the 2009 Warrants are subject to full ratchet anti-dilution adjustment in the event that the Company thereafter issues common stock or common stock equivalents at a price per share less than the conversion price or the exercise price, respectively, and to other normal and customary anti-dilution adjustment upon certain other events. So long as the 2009 Debentures are outstanding, if the Company effects a subsequent financing, the October 2009 Investors may elect, in their sole discretion, to exchange all or some of the October 2009 Debentures (but not the 2009 Warrants) for any securities or units issued in a subsequent financing on a $1.00 for $1.00 basis or to have any particular provisions of the subsequent financing legal documents apply to the documents utilized for the October 2009 Financing. The Company also agreed that if it determines to prepare and file with the Commission a registration statement relating to an offering for its own account or the account of others, then it shall include the shares of common stock underlying the 2009 Securities on such registration statement. The 2009 Investors have contractually agreed to restrict their ability to convert the 2009 Debentures and exercise the 2009 Warrants and receive shares of our common stock such that the number of shares of the Company common stock held by a 2009 Investor and its affiliates after such conversion or exercise does not exceed 4.9% of the Companys then issued and outstanding shares of common stock. During 2010, 2009 Investors converted $1,335,000 of the principal amount of 2009 Debentures for 106,800 shares of the Companys common stock. During 2011, 2009 Investors converted $610,000 of the principal amount of 2009 Debentures for 48,800 shares of the Companys common stock. The Company entered into a Forbearance Agreement on December 3, 2015, pursuant to which the remaining 2009 Debenture holder agreed to refrain and forbear from exercising certain rights and remedies with respect the 2009 Debentures for three months. In exchange for the Forbearance Agreement, the Company issued an allonge in the amount of $250,000 increasing the principal amount of the 2009 Debentures to $305,000 as of March 31,2016. On June 1, 2011, the Company entered into a financing arrangement with several accredited investors (the June 2011 Investors), pursuant to which it sold various securities in consideration of a maximum aggregate purchase price of $500,000 (the June 2011 Financing). In connection with the June 2011 Financing, the Company issued the following securities to the June 2011 Investors: ● 12% Convertible Debentures in the principal amount of $500,000 due April 15, 2012, convertible into shares of the Companys common stock at a per share conversion price equal to $25.00 per share; and ● Warrants to purchase 20,000 of shares of the Companys common stock. The warrants are exercisable, on a cash or cashless basis, for up to two years from the date of issue at a per share exercise price equal to $37.50. During 2015, the exercise price was adjusted to $1.25 and the exercise date was extended to June 2019. In November, 2011, the Company entered into a financing arrangement with several accredited investors (the November 2011 Investors), pursuant to which it sold various securities in consideration of a maximum aggregate purchase price of $275,000 (the November 2011 Financing). In connection with the November 2011 Financing, the Company issued the following securities to the November 2011 Investors: ● 8% Convertible Debentures in the principal amount of $275,000 due in two years, convertible into shares of the Companys common stock at a per share conversion price equal to $12.50 per share; and ● Warrants to purchase 22,000 of shares of the Companys common stock. The Class A Warrants and Class B Warrants (collectively, the Warrants) are exercisable for up to five years from the date of issue at a per share exercise price equal to $15.625 and $18.75 for the Class A Warrants and the Class B Warrants, respectively, on a cash or cashless basis. In March, 2012, the Company entered into a financing arrangement with several accredited investors pursuant to which it sold various securities in consideration of a maximum aggregate purchase price of $617,500 (the March 2012 Financing). In connection with the March 2012 Financing, the Company issued the following securities to the investors: ● 8% Convertible Debentures in the principal amount of $617,500 due in two years, convertible into shares of the Companys common stock at a per share conversion price equal to $12.50 per share; and ● Warrants to purchase 49,400 of shares of the Companys common stock. The Class A Warrants and Class B Warrants (collectively, the March 2012 Warrants) are exercisable for up to five years from the date of issue at a per share exercise price equal $15.625 and $18.75 for the Class A Warrants and the Class B Warrants, respectively, on a cash or cashless basis. In April 2012, the Company agreed to an adjustment as negotiated to enable inducement of further financing of the Company. Pursuant to the anti-dilution provisions in the convertible instruments, the conversion price of certain convertible instruments is now $2.50 (with the exception of the conversion price of the October 2006 Debenture which is already priced at the lesser of $2.50 and 60% of the average of the lowest three trading prices occurring at any time during the 20 trading days preceding conversion). In May, 2012, the Company entered into a financing arrangement with several accredited investors pursuant to which it sold various securities in consideration of a maximum aggregate purchase price of $275,000 (the May 2012 Financing). In connection with the May 2012 Financing, the Company issued the following securities to the investors: ● 8% Convertible Debentures in the principal amount of $275,000 due May 2014, convertible into shares of the Companys common stock at a per share conversion price equal to $12.50 per share; and ● Warrants to purchase 22,000 of shares of the Companys common stock. The Class A Warrants and Class B Warrants (collectively, the May 2012 Warrants) are exercisable for up to five years from the date of issue at a per share exercise price equal to $15.625 and $18.75 for the Class A Warrants and the Class B Warrants, respectively, on a cash or cashless basis. On August 8, 2012, a Settlement Agreement and Mutual General Release ("Agreement") was made by and between OXIS and Bristol Investment Fund, Ltd., in order to settle certain claims regarding certain convertible debentures held by Bristol. Pursuant to the Agreement, OXIS shall pay Bristol (half of which payment would redound to Theorem Capital LLC (Theorem)) a total of $1,119,778 as payment in full for the losses suffered and all costs incurred by Bristol in connection with the Transaction. Payment of such $1,119,778 shall be made as follows: OXIS shall issue restricted common stock to each of Bristol and Merit, in an amount such that each Bristol and Theorem shall hold no more than 9.99% of the outstanding shares of OXIS (including any shares that each may hold as of the date of issuance). The shares so issued represent $417,475.65 of the $1,119,778 payment (111,327 shares at $3.75 per share, of which 36,675 will be retained by Bristol and 74,652 will be issued to Theorem). The remaining balance of the payment shall be made in the form of two convertible promissory notes in the respective amounts of $422,357.75 for Bristol and $279,944.60 for Theorem (collectively, the Notes) with a maturity of December 1, 2017 having an 8% annual interest rate, with interest only accruing until January 1, 2013, and then level payments of $3,750 each beginning January 1, 2013 until paid in full on December 1, 2017. In the event a default in the monthly payments on the Notes has occurred and is continuing each holder of the Notes shall be permitted to convert the unpaid principal and interest of the Notes into shares of OXIS at $2.50 cents per share. In the absence of such continuing default no conversion of the Notes will be permitted. OXIS will have the right to repay the Notes in full at any time without penalty. Effective April, 2013 the Company entered into a securities purchase agreement with one accredited investor to sell 10% convertible debentures with an initial principal balance of $75,000. In October and November, 2013, the Company entered into a securities purchase agreement with four accredited investors to sell 10% convertible debentures with an initial principal balance of $172,000 and warrants to acquire up to 98,286 shares of the Companys common stock at an exercise price of $2.50 per share. In December, 2013, the Company entered into a convertible demand promissory note with an initial principal balance of $189,662 convertible at $1.75 per share and warrants to acquire up to 108,378 shares of the Companys common stock at an exercise price of $2.50 per share. In January, 2014, the Company entered into a securities purchase agreement with one accredited investor to sell 10% convertible debentures with an initial principal balance of $50,000 and warrants to acquire up to 28,571 shares of the Companys common stock at an exercise price of $2.50 per share. In April, 2014, the Company entered into a securities purchase agreement with three accredited investors to sell 10% convertible debentures with an initial principal balance of $49,000 and warrants to acquire up to 22,286 shares of the Companys common stock at an exercise price of $2.50 per share. In July 2014, the Company agreed to an adjustment as negotiated to enable inducement of further financing of the Company. Pursuant to the anti-dilution provisions in the convertible instruments, the conversion price of certain convertible instruments is now $1.75 (with the exception of the conversion price of the October 2006 Debenture which is already priced at the lesser of $1.75 and 60% of the average of the lowest three trading prices occurring at any time during the 20 trading days preceding conversion). On July 24, 2014, the Company entered into a securities purchase agreement with ten accredited investors to sell 10% convertible debentures, with an exercise price of $1.75, with an initial principal balance of $1,250,000 and warrants to acquire up to 714,286 shares of the Companys common stock at an exercise price of $2.50 per share. Also on July 24, 2014, the Company sold to Kenneth Eaton, the Companys Chief Executive Officer, a $175,000 debenture, with an exercise price of $1.75, as payment in full for all accrued and unpaid salary and fees owed to Mr. Eaton. This note was converted on the second quarter of 2016. On October 15, 2014, the Company entered into a securities purchase agreement with three accredited investors to sell 10% convertible debentures, with an exercise price of $2.50, with an initial principal balance of $1,250,000 and warrants to acquire up to 400,000 shares of the Companys common stock at an exercise price of $5.00 per share. On February 23, 2015, the Company entered into a securities purchase agreement with ten accredited investors to sell 10% convertible debentures, with an exercise price of $6.25, with an initial principal balance of $2,350,000 and warrants to acquire up to 376,000 shares of the Companys common stock at an exercise price of $7.50 per share. Effective July 2015, the Company entered into a securities purchase agreement with three accredited investors to sell 10% convertible debentures, with an exercise price of $5.00, with an initial principal balance of $550,000 and warrants to acquire up to 111,765 shares of the Companys common stock at an exercise price of $6.25 per share. Effective October 2015, the Company entered into a securities purchase agreement with three accredited investors to sell 10% convertible debentures, with an exercise price of $2.50, with an initial principal balance of $500,000 and warrants to acquire up to 200,000 shares of the Companys common stock at an exercise price of $2.50 per share. Effective November 2015, the Company entered into a securities purchase agreement with two accredited investors to sell 10% convertible debentures, with an exercise price of $2.50, with an initial principal balance of $100,000 and warrants to acquire up to 80,000 shares of the Companys common stock at an exercise price of $2.50 per share. Effective December 2015, the Company entered into a securities purchase agreement with two accredited investors to sell 10% convertible debentures, with and an exercise price of $1.25, with an initial principal balance of $350,000 and warrants to acquire up to 280,000 shares of the Companys common stock at an exercise price of $1.25 per share. In December 2015, the Company agreed to an adjustment as negotiated to enable inducement of further financing of the Company. Pursuant to the anti-dilution provisions in all the convertible instruments, the conversion price of certain convertible instruments is now $1.25 (with the exception of the conversion price of the October 2006 Debenture which is already priced at the lesser of $1.25 and 60% of the average of the lowest three trading prices occurring at any time during the 20 trading days preceding conversion). In January 2016, the Company entered into a securities purchase agreement with one accredited investor to sell 10% convertible debentures, with and an exercise price of $1.25, with an initial principal balance of $150,000 and warrants to acquire up to 80,000 shares of the Companys common stock at an exercise price of $1.25 per share. In May 2016, the Company entered into a securities purchase agreement with twenty accredited investors to sell 10% convertible debentures, with and an exercise price of $0.40, with an initial principal balance of $1,390,044 and warrants to acquire up to 3,475,111 shares of the Companys common stock at an exercise price of $0.45 per share. Allonges On August 18, 2015, the Company entered into a settlement agreement with three noteholders. In accordance with the July 24, 2014 Security Purchase Agreements, The Company was required to establish and maintain a reserve of shares of its common stock from its duly authorized shares of Common Stock for issuance in an amount equal to 150% of a required minimum by December 21, 2014 which did not occur. As compensation for the default, the Company issued allonges to the noteholders for a total of $837,500, increasing the principal amount of the convertible notes. On October 7, 2015, the Company entered into a settlement agreement with two noteholders. In accordance with the July 24, 2014 Security Purchase Agreements, The Company was required to establish and maintain a reserve of shares of its common stock from its duly authorized shares of Common Stock for issuance in an amount equal to 150% of a required minimum by December 21, 2014 which did not occur. As compensation for the default, the Company issued allonges to the noteholders for a total of $537,500, increasing the principal amount of the convertible notes. On November 5, 2015, the Company entered into a Second Settlement Agreement with three noteholders. On August 18, 2015 the Company entered into a Settlement Agreement that required the Company to increase its authorized shares to not less 8,000,000 shares and reserve 150% of the number of shares of its Common Stock no later than the earlier of (1) two days after Oxis obtaining all corporate and regulatory approvals necessary to increase it authorized shares; or (2) September 30, 2015 which did not occur. As compensation for the default, the Company issued additional allonges to the noteholders for a total of $837,500, increasing the principal amount of the convertible notes. On Dec 5, 2015, the Company entered into a Second Settlement Agreement with three noteholders. On October 7, 2015 the Company entered into a Settlement Agreement that required the Company to increase its authorized shares to not less than 8,000,000 shares and reserve 150% of the number of shares of its Common Stock no later than the earlier of (1) two days after Oxis obtaining all corporate and regulatory approvals necessary to increase it authorized shares; or (2) September 30, 2015 which did not occur. As compensation for the default, the Company issued additional allonges to the noteholders for a total of $537,500, increasing the principal amount of the convertible notes. Demand Notes On May 15, 2009, the Company entered into a convertible demand promissory note with Bristol Capital, LLC for certain consulting services totaling $100,000. The note does not provide for any interest and is due upon demand by the holder. The note has been converted into common stock of the Company. On June 22, 2009, the Company entered into a convertible demand promissory note with Theorem Group (Theorem) pursuant to which Theorem purchased an aggregate principal amount of $31,375 of convertible demand promissory notes for an aggregate purchase price of $25,000 (the 2009 Theorem Note). The 2009 Theorem Note was subsequently sold as described below. Simultaneously with the issuance of the 2009 Theorem Note, the Company issued Theorem a seven-year warrant (the 2009 Theorem Warrant) to purchase 12,550 shares of common stock of the Company at a price equal to the lower of (i) $2.50 and (ii) 60% of the average of the three (3) lowest trading prices occurring at any time during the 20 trading days preceding the issue date of the Theorem Note (the Exercise Price). The 2009 Theorem Warrant may be exercised on a cashless basis if the shares of common stock underlying the 2009 Theorem Warrant are not then registered pursuant to an effective registration statement. In the event the 2009 Theorem Warrant is exercised on a cashless basis, we will not receive any proceeds. On December 1, 2009, Theorem sold the 2009 Theorem Note to Net Capital Partners, Inc. (Net Capital). In December 2009, Net Capital converted $24,000 of the principal for 9,600 shares of the Companys common stock. In January 2010, Net Capital converted the remaining $7,375 of principal amount for an additional 2,950 shares of the Companys common stock. On February 7, 2011 the Company entered into a convertible demand promissory note with Bristol pursuant to which Bristol purchased an aggregate principal amount of $31,375 of convertible demand promissory notes for an aggregate purchase price of $25,000 (the February 2011 Bristol Note). The February 2011 Bristol Note is convertible into shares of common stock of the Company at a price equal to $12.50 per share. Simultaneously with the issuance of the February 2011 Bristol Note, the Company issued Bristol a Series A Warrant (the February 2011 Bristol Series A Warrants) to purchase 1,255 shares of the Companys common stock at a per share exercise price of $15.625, and a Series B Warrant (the February 2011 Bristol Series B Warrants and, together with the February 2011 Bristol Series A Warrants, the February 2011 Bristol Warrants) to purchase 1,255 shares of the Companys common stock at a per share exercise price of $18.75. The February 2011 Warrants are exercisable for up to seven years from the date of issue. The February 2011 Warrants may be exercised on a cashless basis if the shares of common stock underlying the February 2011 Warrants are not then registered pursuant to an effective registration statement. In the event the February 2011 Bristol Warrants are exercised on a cashless basis, the Company will not receive any proceeds. On February 7, 2011 the Company entered into a convertible demand promissory note with Net Capital pursuant to which Net Capital purchased an aggregate principal amount of $31,375 of convertible demand promissory notes for an aggregate purchase price of $25,000 (the February 2011 Net Capital Note). The February 2011 Net Capital Note is convertible into shares of common stock of the Company at a price equal to $12.50 per share. As of September, 2012, the February 2011 Net Capital Note had been converted into shares of the Companys common stock. Simultaneously with the issuance of the February 2011 Net Capital Note, the Company issued Net Capital a Series A Warrant (the February 2011 Net Capital Series A Warrants) to purchase 1,255 shares of the Companys common stock at a per share exercise price of $15.625, and a Series B Warrant (the February 2011 Net Capital Series B Warrants and, together with the February 2011 Net Capital Series A Warrants, the February 2011 Net Capital Warrants) to purchase 1,255 shares of the Companys common stock at a per share exercise price of $18.75. The February 2011 Net Capital Warrants are exercisable for up to seven years from the date of issue. The February 2011 Net Capital Warrants may be exercised on a cashless basis if the shares of common stock underlying the February 2011 Net Capital Warrants are not then registered pursuant to an effective registration statement. In the event the February 2011 Net Capital Warrants are exercised on a cashless basis, the Company will not receive any proceeds. On March 4, 2011 the Company entered into a convertible demand promissory note with Bristol pursuant to which Bristol purchased an aggregate principal amount of $31,375 of convertible demand promissory notes for an aggregate purchase price of $25,000 (the March 2011 Bristol Note). The March 2011 Bristol Note is convertible at the option of the holder at any time into shares of common stock, at a price equal to $12.50. Simultaneously with the issuance of the March 2011 Bristol Note, the Company issued Bristol a Series A Warrant (the March 2011 Bristol Series A Warrants) to purchase 1,255 shares of the Companys common stock at a per share exercise price of $15.625, and a Series B Warrant (the March 2011 Bristol Series B Warrants and, together with the March 2011 Bristol Series A Warrants, (the March 2011 Bristol Warrants) to purchase 1,255 shares of the Companys common stock at a per share exercise price of $18.75. The March 2011 Warrants are exercisable for up to seven years from the date of issue. The March 2011 Warrants may be exercised on a cashless basis if the shares of common stock u | Convertible debentures On October 25, 2006, the Company entered into a securities purchase agreement (2006 Purchase Agreement) with four accredited investors (the 2006 Purchasers). In conjunction with the signing of the 2006 Purchase Agreement, the Company issued secured convertible debentures (2006 Debentures) and Series A, B, C, D, and E common stock warrants (2006 Warrants) to the 2006 Purchasers, and the parties also entered into a security agreement (the 2006 Security Agreement) pursuant to which the Company agreed to grant the 2006 Purchasers, pari passu, a security interest in substantially all of the Companys assets. Pursuant to the terms of the 2006 Purchase Agreement, the Company issued the 2006 Debentures in an aggregate principal amount of $1,694,250 to the 2006 Purchasers. The 2006 Debentures are subject to an original issue discount of 20.318% resulting in proceeds to the Company of $1,350,000 from the transaction. The 2006 Debentures were due on October 25, 2008. The 2006 Debentures are convertible, at the option of the 2006 Purchasers, at any time prior to payment in full, into shares of common stock of the Company. As a result of the full ratchet anti-dilution provision the current conversion price is $2.50 per share (the 2006 Conversion Price). Beginning on the first of the month beginning February 1, 2007, the Company was required to amortize the 2006 Debentures in equal installments on a monthly basis resulting in a complete repayment by the maturity date (the Monthly Redemption Amounts). The Monthly Redemption Amounts could have been paid in cash or in shares, subject to certain restrictions. If the Company chose to make any Monthly Redemption Amount payment in shares of common stock, the price per share would have been the lesser of the Conversion Price then in effect and 85% of the weighted average price for the 10-trading days prior to the due date of the Monthly Redemption Amount. The Company did not make any of the required monthly redemption payments. Pursuant to the provisions of the 2006 Debentures, such non-payment was an event of default and penalty interest has accrued on the unpaid redemption balance at an interest rate equal to the lower of 18% per annum and the maximum rate permitted by applicable law. In addition, each of the 2006 Purchasers has the right to accelerate the cash repayment of at least 130% of the outstanding principal amount of the 2006 Debenture (plus accrued but unpaid liquidated damages and interest) and to sell substantially all of the Companys assets pursuant to the provisions of the 2006 Security Agreement to satisfy any such unpaid balance. On June 6, 2008, the Company received notification from Bristol Investment Fund, Ltd (Bristol), that the collateral held under the 2006 Security Agreement would be sold to the highest qualified bidder on Thursday, June 19, 2008. On June 19, 2008, the Company received a Notice of Disposition of Collateral from Bristol in which Bristol notified the Company that Bristol, acting as the agent for itself and the three other 2006 Purchasers, purchased certain assets held as collateral under the 2006 Security Agreement. Bristol purchased 111,025 shares of common stock of BioCheck, Inc., the Companys majority owned subsidiary, on a credit bid of $50,000, and Bristol also purchased 1,000 shares of the capital stock of OXIS Therapeutics, Inc., a wholly owned subsidiary of OXIS, for a credit bid of $10,000. In December 2005, OXIS purchased the 111,025 shares of common stock of BioCheck, Inc. for $3,060,000. After crediting the aggregate amount of $60,000 to the aggregate amount due under the 2006 Debentures, plus fees and charges due through June 19, 2008, Bristol notified the Company that the Company remains obligated to the 2006 Purchasers in a deficiency in an aggregate amount of $2,688,000 as of June 19, 2008. As a result of the disposition of the collateral, the Company recorded a net loss aggregating $2,978,000. Under the 2006 Purchase Agreement, the 2006 Purchasers also have a right of first refusal to participate in up to 100% of any future financing undertaken by the Company until the 2006 Debentures are no longer outstanding. In addition, the Company is also prohibited from effecting any subsequent financing involving a variable rate transaction until such time as no 2006 Purchaser holds any of the 2006 Debentures. Furthermore, so long as any 2006 Purchaser holds any of the securities issued under the 2006 Purchase Agreement, if the Company issues or sells any common stock or instruments convertible into common stock which a 2006 Purchaser reasonably believes is on terms more favorable to such investors than the terms pursuant to the 2006 Debentures or 2006 Warrants, the Company is obligated to permit such 2006 Purchaser the benefits of such better terms. Of the 2006 Warrants issued by the Company to the 2006 Purchasers, only the Series A Warrants remain outstanding. The Series A Warrants, which now expire in July 2019, permit the holders to purchase 9,681 shares of common stock at an original exercise price of $87.50 per share. Such exercise price is adjustable pursuant to a full ratchet anti-dilution provision and upon the occurrence of a stock split or a related event. During 2009, Bristol converted $177,900 of the principal amount of 2006 Debentures for 71,160 shares of the Companys common stock. During 2010, Bristol converted an additional $401,000 of the principal amount of 2006 Debentures for 160,400 shares of the Companys common stock. During 2011, an additional $605,000 of the principal amount of 2006 Debentures was converted into 242,000 shares of the Companys common stock. During 2012, an additional $369,625 of the principal amount of 2006 Debentures was converted into 350,619 shares of the Companys common stock. The 2006 Debentures do not meet the definition of a conventional convertible debt instrument since they are not convertible into a fixed number of shares. The Monthly Redemption Amounts can be paid with common stock at a conversion price that is a percentage of the market price; therefore the number of shares that could be required to be delivered upon net-share settlement is essentially indeterminate. Therefore, the 2006 Debentures are considered non-conventional, which means that the conversion feature must be bifurcated from the debt and shown as a separate derivative liability. This beneficial conversion liability has been calculated to be $690,000 on October 25, 2006. In addition, since the 2006 Debentures are convertible into an indeterminate number of shares of common stock, it is assumed that the Company could never have enough authorized and unissued shares to settle the conversion of the 2006 Warrants issues in this transaction into common stock. Therefore, the 2006 Warrants have a fair value of $2,334,000 at October 25, 2006. The value of the 2006 Warrant was calculated using the Black-Scholes model using the following assumptions: Discount rate of 4.5%, volatility of 158% and expected term of 1 to 6 years. The fair value of the beneficial conversion feature and the 2006 Warrant liability will be adjusted to fair value on each balance sheet date with the change being shown as a component of net loss. The fair value of the beneficial conversion feature and the 2006 Warrants at the inception of the 2006 Debentures were $690,000 and $2,334,000, respectively. The first $1,350,000 of these discounts was amortized over the term of the 2006 Debenture and the excess of $1,674,000 was shown as financing costs in statement of operations. The Company and Bristol entered into a Forbearance Agreement on December 3, 2015, pursuant to which Bristol agreed to refrain and forbear from exercising certain rights and remedies with respect the 2006 Debentures for three months. In exchange for the Forbearance Agreement, the Company issued an allonge in the amount of $250,000 increasing the principal amount if the 2006 Debentures. On October 1, 2009, the Company entered into a financing arrangement with several accredited investors (the 2009 Investors), pursuant to which it sold various securities in consideration of a maximum aggregate purchase price of $2,000,000 (the 2009 Financing). In connection with the 2009 Financing, the Company issued the following securities to the 2009 Investors: · 0% Convertible Debentures in the principal amount of $2,000,000 due 24 months from the date of issuance (the 2009 Debentures), convertible into shares of the Companys common stock at a per share conversion price equal to $12.50 per share; · Series A warrant to purchase such number of shares of the Companys common stock equal to 50% of the principal amount invested by each 2009 Investor (the 2009 Class A Warrants ) resulting in the issuance of Class A Warrants to purchase 80,000 shares of common stock of the Company. · Series B warrant to purchase such number of shares of the Companys common stock equal to 50% of the principal amount invested by each 2009 Investor (the 2009 Class B Warrants) resulting in the issuance of Class B Warrants to purchase 80,000 shares of common stock of the Company. The Class A Warrants and Class B Warrants (collectively, the 2009 Warrants) are exercisable for up to five years from the date of issue at a per share exercise price equal to $15.625 and $18.75 for the Class A Warrants and the Class B Warrants, respectively, on a cash or cashless basis. The 2009 Debentures and the 2009 Warrants are collectively referred to herein as the 2009 Securities. In connection with the sale of the 2009 Securities by the Company, the Company and Bristol entered a Standstill and Forbearance Agreement, pursuant to which Bristol agreed to refrain and forbear from exercising certain rights and remedies with respect to (i) the 2006 Debentures and (ii) certain demand notes (the Bridge Notes) issued by the Company on October 8, 2008, March 19, 2009, April 7, 2009, April 28, 2009, May 21, 2009 and June 25, 2009 and discussed under the caption Demand Notes below. In connection with the sale of the 2009 Securities by the Company, the Company and Bristol have also entered into a waiver agreement (the Waiver Agreement) pursuant to which Bristol waived certain rights with respect to the 2006 Debentures and Bridge Notes. The conversion price of the 2009 Debentures and the exercise price of the 2009 Warrants are subject to full ratchet anti-dilution adjustment in the event that the Company thereafter issues common stock or common stock equivalents at a price per share less than the conversion price or the exercise price, respectively, and to other normal and customary anti-dilution adjustment upon certain other events. So long as the 2009 Debentures are outstanding, if the Company effects a subsequent financing, the October 2009 Investors may elect, in their sole discretion, to exchange all or some of the October 2009 Debentures (but not the 2009 Warrants) for any securities or units issued in a subsequent financing on a $1.00 for $1.00 basis or to have any particular provisions of the subsequent financing legal documents apply to the documents utilized for the October 2009 Financing. The Company also agreed that if it determines to prepare and file with the Commission a registration statement relating to an offering for its own account or the account of others, then it shall include the shares of common stock underlying the 2009 Securities on such registration statement. The 2009 Investors have contractually agreed to restrict their ability to convert the 2009 Debentures and exercise the 2009 Warrants and receive shares of our common stock such that the number of shares of the Company common stock held by a 2009 Investor and its affiliates after such conversion or exercise does not exceed 4.9% of the Companys then issued and outstanding shares of common stock. During 2010, 2009 Investors converted $1,335,000 of the principal amount of 2009 Debentures for 106,800 shares of the Companys common stock. During 2011, 2009 Investors converted $610,000 of the principal amount of 2009 Debentures for 48,800 shares of the Companys common stock. Accordingly, at December 31, 2015, $55,000 in aggregate principal amount of 2009 Debentures remained outstanding. The Company entered into a Forbearance Agreement on December 3, 2015, pursuant to which the remaining 2009 Debenture holder agreed to refrain and forbear from exercising certain rights and remedies with respect the 2009 Debentures for three months. In exchange for the Forbearance Agreement, the Company issued an allonge in the amount of $250,000 increasing the principal amount of the 2009 Debentures. On June 1, 2011, the Company entered into a financing arrangement with several accredited investors (the June 2011 Investors), pursuant to which it sold various securities in consideration of a maximum aggregate purchase price of $500,000 (the June 2011 Financing). In connection with the June 2011 Financing, the Company issued the following securities to the June 2011 Investors: · 12% Convertible Debentures in the principal amount of $500,000 due April 15, 2012, convertible into shares of the Companys common stock at a per share conversion price equal to $25.00 per share; and · Warrants to purchase 20,000 of shares of the Companys common stock. The warrants are exercisable, on a cash or cashless basis, for up to two years from the date of issue at a per share exercise price equal to $37.50. During 2015, the exercise price was adjusted to $1.25 and the exercise date was extended to June 2019. In November, 2011, the Company entered into a financing arrangement with several accredited investors (the November 2011 Investors), pursuant to which it sold various securities in consideration of a maximum aggregate purchase price of $275,000 (the November 2011 Financing). In connection with the November 2011 Financing, the Company issued the following securities to the November 2011 Investors: · 8% Convertible Debentures in the principal amount of $275,000 due in two years, convertible into shares of the Companys common stock at a per share conversion price equal to $12.50 per share; and · Warrants to purchase 22,000 of shares of the Companys common stock. The Class A Warrants and Class B Warrants (collectively, the Warrants) are exercisable for up to five years from the date of issue at a per share exercise price equal to $15.625 and $18.75 for the Class A Warrants and the Class B Warrants, respectively, on a cash or cashless basis. In March, 2012, the Company entered into a financing arrangement with several accredited investors pursuant to which it sold various securities in consideration of a maximum aggregate purchase price of $617,500 (the March 2012 Financing). In connection with the March 2012 Financing, the Company issued the following securities to the investors: · 8% Convertible Debentures in the principal amount of $617,500 due in two years, convertible into shares of the Companys common stock at a per share conversion price equal to $12.50 per share; and · Warrants to purchase 49,400 of shares of the Companys common stock. The Class A Warrants and Class B Warrants (collectively, the March 2012 Warrants) are exercisable for up to five years from the date of issue at a per share exercise price equal $15.625 and $18.75 for the Class A Warrants and the Class B Warrants, respectively, on a cash or cashless basis. In April 2012, the Company agreed to an adjustment as negotiated to enable inducement of further financing of the Company. Pursuant to the anti-dilution provisions in the convertible instruments, the conversion price of certain convertible instruments is now $2.50 (with the exception of the conversion price of the October 2006 Debenture which is already priced at the lesser of $2.50 and 60% of the average of the lowest three trading prices occurring at any time during the 20 trading days preceding conversion). In May, 2012, the Company entered into a financing arrangement with several accredited investors pursuant to which it sold various securities in consideration of a maximum aggregate purchase price of $275,000 (the May 2012 Financing). In connection with the May 2012 Financing, the Company issued the following securities to the investors: · 8% Convertible Debentures in the principal amount of $275,000 due May 2014, convertible into shares of the Companys common stock at a per share conversion price equal to $12.50 per share; and · Warrants to purchase 22,000 of shares of the Companys common stock. The Class A Warrants and Class B Warrants (collectively, the May 2012 Warrants) are exercisable for up to five years from the date of issue at a per share exercise price equal to $15.625 and $18.75 for the Class A Warrants and the Class B Warrants, respectively, on a cash or cashless basis. On August 8, 2012, a Settlement Agreement and Mutual General Release ("Agreement") was made by and between OXIS and Bristol Investment Fund, Ltd., in order to settle certain claims regarding certain convertible debentures held by Bristol. Pursuant to the Agreement, OXIS shall pay Bristol (half of which payment would redound to Theorem Capital LLC (Theorem)) a total of $1,119,778 as payment in full for the losses suffered and all costs incurred by Bristol in connection with the Transaction. Payment of such $1,119,778 shall be made as follows: OXIS shall issue restricted common stock to each of Bristol and Merit, in an amount such that each Bristol and Theorem shall hold no more than 9.99% of the outstanding shares of OXIS (including any shares that each may hold as of the date of issuance). The shares so issued represent $417,475.65 of the $1,119,778 payment (111,327 shares at $3.75 per share, of which 36,675 will be retained by Bristol and 74,652 will be issued to Theorem). The remaining balance of the payment shall be made in the form of two convertible promissory notes in the respective amounts of $422,357.75 for Bristol and $279,944.60 for Theorem (collectively, the Notes) with a maturity of December 1, 2017 having an 8% annual interest rate, with interest only accruing until January 1, 2013, and then level payments of $3,750 each beginning January 1, 2013 until paid in full on December 1, 2017. In the event a default in the monthly payments on the Notes has occurred and is continuing each holder of the Notes shall be permitted to convert the unpaid principal and interest of the Notes into shares of OXIS at $2.50 cents per share. In the absence of such continuing default no conversion of the Notes will be permitted. OXIS will have the right to repay the Notes in full at any time without penalty. Effective April, 2013 the Company entered into a securities purchase agreement with one accredited investor to sell 10% convertible debentures with an initial principal balance of $75,000. In October and November, 2013, the Company entered into a securities purchase agreement with four accredited investors to sell 10% convertible debentures with an initial principal balance of $172,000 and warrants to acquire up to 98,286 shares of the Companys common stock at an exercise price of $2.50 per share. In December, 2013, the Company entered into a convertible demand promissory note with an initial principal balance of $189,662 convertible at $1.75 per share and warrants to acquire up to 108,378 shares of the Companys common stock at an exercise price of $2.50 per share. In January, 2014, the Company entered into a securities purchase agreement with one accredited investor to sell 10% convertible debentures with an initial principal balance of $50,000 and warrants to acquire up to 28,571 shares of the Companys common stock at an exercise price of $2.50 per share. In April, 2014, the Company entered into a securities purchase agreement with three accredited investors to sell 10% convertible debentures with an initial principal balance of $49,000 and warrants to acquire up to 22,286 shares of the Companys common stock at an exercise price of $2.50 per share. In July 2014, the Company agreed to an adjustment as negotiated to enable inducement of further financing of the Company. Pursuant to the anti-dilution provisions in the convertible instruments, the conversion price of certain convertible instruments is now $1.75 (with the exception of the conversion price of the October 2006 Debenture which is already priced at the lesser of $1.75 and 60% of the average of the lowest three trading prices occurring at any time during the 20 trading days preceding conversion). On July 24, 2014, the Company entered into a securities purchase agreement with ten accredited investors to sell 10% convertible debentures, with an exercise price of $1.75, with an initial principal balance of $1,250,000 and warrants to acquire up to 714,286 shares of the Companys common stock at an exercise price of $2.50 per share. Also on July 24, 2014, the Company sold to Kenneth Eaton, the Companys Chief Executive Officer, a $175,000 debenture, with an exercise price of $1.75, as payment in full for all accrued and unpaid salary and fees owed to Mr. Eaton. On October 15, 2014, the Company entered into a securities purchase agreement with three accredited investors to sell 10% convertible debentures, with an exercise price of $2.50, with an initial principal balance of $1,250,000 and warrants to acquire up to 400,000 shares of the Companys common stock at an exercise price of $5.00 per share. On February 23, 2015, the Company entered into a securities purchase agreement with ten accredited investors to sell 10% convertible debentures, with an exercise price of $6.25, with an initial principal balance of $2,350,000 and warrants to acquire up to 376,000 shares of the Companys common stock at an exercise price of $7.50 per share. Effective July 2015, the Company entered into a securities purchase agreement with three accredited investors to sell 10% convertible debentures, with an exercise price of $5.00, with an initial principal balance of $550,000 and warrants to acquire up to 111,765 shares of the Companys common stock at an exercise price of $6.25 per share. Effective October 2015, the Company entered into a securities purchase agreement with three accredited investors to sell 10% convertible debentures, with an exercise price of $2.50, with an initial principal balance of $500,000 and warrants to acquire up to 200,000 shares of the Companys common stock at an exercise price of $2.50 per share. Effective November 2015, the Company entered into a securities purchase agreement with two accredited investors to sell 10% convertible debentures, with an exercise price of $2.50, with an initial principal balance of $100,000 and warrants to acquire up to 80,000 shares of the Companys common stock at an exercise price of $2.50 per share. Effective December 2015, the Company entered into a securities purchase agreement with two accredited investors to sell 10% convertible debentures, with and an exercise price of $1.25, with an initial principal balance of $350,000 and warrants to acquire up to 280,000 shares of the Companys common stock at an exercise price of $1.25 per share. In December 2015, the Company agreed to an adjustment as negotiated to enable inducement of further financing of the Company. Pursuant to the anti-dilution provisions in all the convertible instruments, the conversion price of certain convertible instruments is now $1.25 (with the exception of the conversion price of the October 2006 Debenture which is already priced at the lesser of $1.25 and 60% of the average of the lowest three trading prices occurring at any time during the 20 trading days preceding conversion). Allonges On August 18, 2015, the Company entered into a settlement agreement with three noteholders. In accordance with the July 24, 2014 Security Purchase Agreements, The Company was required to establish and maintain a reserve of shares of its common stock from its duly authorized shares of Common Stock for issuance in an amount equal to 150% of a required minimum by December 21, 2014 which did not occur. As compensation for the default, the Company issued allonges to the noteholders for a total of $812,500, increasing the principal amount of the convertible notes. On October 7, 2015, the Company entered into a settlement agreement with two noteholders. In accordance with the July 24, 2014 Security Purchase Agreements, The Company was required to establish and maintain a reserve of shares of its common stock from its duly authorized shares of Common Stock for issuance in an amount equal to 150% of a required minimum by December 21, 2014 which did not occur. As compensation for the default, the Company issued allonges to the noteholders for a total of $537,500, increasing the principal amount of the convertible notes. On November 5, 2015, the Company entered into a Second Settlement Agreement with three noteholders. On August 18, 2015 the Company entered into a Settlement Agreement that required the Company to increase its authorized shares to not less 8,000,000 shares and reserve 150% of the number of shares of its Common Stock no later than the earlier of (1) two days after Oxis obtaining all corporate and regulatory approvals necessary to increase it authorized shares; or (2) September 30, 2015 which did not occur. As compensation for the default, the Company issued additional allonges to the noteholders for a total of $837,500, increasing the principal amount of the convertible notes. On Dec 5, 2015, the Company entered into a Second Settlement Agreement with three noteholders. On October 7, 2015 the Company entered into a Settlement Agreement that required the Company to increase its authorized shares to not less than 8,000,000 shares and reserve 150% of the number of shares of its Common Stock no later than the earlier of (1) two days after Oxis obtaining all corporate and regulatory approvals necessary to increase it authorized shares; or (2) September 30, 2015 which did not occur. As compensation for the default, the Company issued additional allonges to the noteholders for a total of $537,500, increasing the principal amount of the convertible notes. Demand Notes On May 15, 2009, the Company entered into a convertible demand promissory note with Bristol Capital, LLC for certain consulting services totaling $100,000. The note does not provide for any interest and is due upon demand by the holder. The note has been converted into common stock of the Company. On June 22, 2009, the Company entered into a convertible demand promissory note with Theorem Group (Theorem) pursuant to which Theorem purchased an aggregate principal amount of $31,375 of convertible demand promissory notes for an aggregate purchase price of $25,000 (the 2009 Theorem Note). The 2009 Theorem Note was subsequently sold as described below. Simultaneously with the issuance of the 2009 Theorem Note, the Company issued Theorem a seven-year warrant (the 2009 Theorem Warrant) to purchase 12,550 shares of common stock of the Company at a price equal to the lower of (i) $2.50 and (ii) 60% of the average of the three (3) lowest trading prices occurring at any time during the 20 trading days preceding the issue date of the Theorem Note (the Exercise Price). The 2009 Theorem Warrant may be exercised on a cashless basis if the shares of common stock underlying the 2009 Theorem Warrant are not then registered pursuant to an effective registration statement. In the event the 2009 Theorem Warrant is exercised on a cashless basis, we will not receive any proceeds. On December 1, 2009, Theorem sold the 2009 Theorem Note to Net Capital Partners, Inc. (Net Capital). In December 2009, Net Capital converted $24,000 of the principal for 9,600 shares of the Companys common stock. In January 2010, Net Capital converted the remaining $7,375 of principal amount for an additional 2,950 shares of the Companys common stock. On February 7, 2011 the Company entered into a convertible demand promissory note with Bristol pursuant to which Bristol purchased an aggregate principal amount of $31,375 of convertible demand promissory notes for an aggregate purchase price of $25,000 (the February 2011 Bristol Note). The February 2011 Bristol Note is convertible into shares of common stock of the Company at a price equal to $12.50 per share. Simultaneously with the issuance of the February 2011 Bristol Note, the Company issued Bristol a Series A Warrant (the February 2011 Bristol Series A Warrants) to purchase 1,255 shares of the Companys common stock at a per share exercise price of $15.625, and a Series B Warrant (the February 2011 Bristol Series B Warrants and, together with the February 2011 Bristol Series A Warrants, the February 2011 Bristol Warrants) to purchase 1,255 shares of the Companys common stock at a per share exercise price of $18.75. The February 2011 Warrants are exercisable for up to seven years from the date of issue. The February 2011 Warrants may be exercised on a cashless basis if the shares of common stock underlying the February 2011 Warrants are not then registered pursuant to an effective registration statement. In the event the February 2011 Bristol Warrants are exercised on a cashless basis, the Company will not receive any proceeds. On February 7, 2011 the Company entered into a convertible demand promissory note with Net Capital pursuant to which Net Capital purchased an aggregate principal amount of $31,375 of convertible demand promissory notes for an aggregate purchase price of $25,000 (the February 2011 Net Capital Note). The February 2011 Net Capital Note is convertible into shares of common stock of the Company at a price equal to $12.50 per share. As of September, 2012, the February 2011 Net Capital Note had been converted into shares of the Companys common stock. Simultaneously with the issuance of the February 2011 Net Capital Note, the Company issued Net Capital a Series A Warrant (the February 2011 Net Capital Series A Warrants) to purchase 1,255 shares of the Companys common stock at a per share exercise price of $15.625, and a Series B Warrant (the February 2011 Net Capital Series B Warrants and, together with the February 2011 Net Capital Series A Warrants, the February 2011 Net Capital Warrants) to purchase 1,255 shares of the Companys common stock at a per share exercise price of $18.75. The February 2011 Net Capital Warrants are exercisable for up to seven years from the date of issue. The February 2011 Net Capital Warrants may be exercised on a cashless basis if the shares of common stock underlying the February 2011 Net Capital Warrants are not then registered pursuant to an effective registration statement. In the event the February 2011 Net Capital Warrants are exercised on a cashless basis, the Company will not receive any proceeds. On March 4, 2011 the Company entered into a convertible demand promissory note with Bristol pursuant to which Bristol purchased an aggregate principal amount of $31,375 of convertible demand promissory notes for an aggregate purchase price of $25,000 (the March 2011 Bristol Note). The March 2011 Bristol Note is convertible at the option of the holder at any time into shares of common stock, at a price equal to $12.50. Simultaneously with the issuance of the March 2011 Bristol Note, the Company issued Bristol a Series A Warrant (the March 2011 Bristol Series A Warrants) to purchase 1,255 shares of the Companys common stock at a per share exercise price of $15.625, and a Series B Warrant (the March 2011 Bristol Series B Warrants and, together with the March 2011 Bristol Series A Warrants, (the March 2011 Bristol Warrants) to purchase 1,255 shares of the Companys common stock at a per share exercise price of $18.75. The March 2011 Warrants are exercisable for up to seven years from the date of issue. The March 2011 Warrants may be exercised on a cashless basis if the shares of common stock underlying the March 2011 Warrants are not then registered pursuant to an effective registration statement. In the event the March 2011 Warrants are exercised on a cashless basis, the Company will not receive any proceeds. On April 4, 2011 the Company entered into a convertible demand promissory note with Net Capital pursuant to which Net Capital purchased an aggregate principal amount of $31,375 of convertible demand promissory notes for an aggregate purchase price of $25,000 (the April 2011 Net Capital Note). The April 2011 Net Capital Note is convertible into shares of common stock of the Company, at a price equal to $12.50 per share. As of |
Note 4 - Stockholders' Equity
Note 4 - Stockholders' Equity | 6 Months Ended | 12 Months Ended |
Jun. 30, 2016 | Dec. 31, 2015 | |
Equity [Abstract] | ||
Note 4 - Stockholders' Equity | Common Stock In January 2015, the Company agreed to issue 39,657 shares of common stock as a price protection to a note holder that originally converted notes at a price of $2.50 and continues to hold these shares. These additional shares would have been issued if the conversion shares price was $1.75. As of December 31, 2015, 33,142 shares of common stock have been issued and $247,000 of interest expense was recorded for this issuance. During January 2016 the remaining 6,515 share were issued and $20,000 of interest expense was recorded. During the six months ending June 30, 2016, the Company issued an (2) of the Act since the shares were issued to persons or entities closely associated with the Company and there was no public offering of the shares. During the six months ending June 30, 2016, the Company also issued an Section 4(2) of the Act since the shares were also issued to persons closely associated with the Company and there was no public offering of the shares. During the six months ending June 30, 2016, the Company also issued an aggregate of 4,612,341 shares of common stock to two executive officers of the Company in fulfilment of contractual rights held by the officers pursuant to their employment agreements. These shares were also exempt from the registration requirements of Section 5 of the Act pursuant to Section 4(2) of the Act since the shares were also issued to persons closely associated with the Company and there was no public offering of the shares. During the six months ending June 30, 2016, the Company also issued an Section 4(2) of the Act since the shares were also issued to persons closely associated with the Company and there was no public offering of the shares. Preferred Stock On January 8, 2016 the Company entered into an Exchange Agreement with certain investors together holding 25,000 shares of Series H Preferred Stock and 1,666,667 shares of Series I Preferred Stock have agreed to convert all such shares of Preferred Stock into an aggregate of 4,075,000 shares of Common Stock upon successful completion by the Company of a $6 million financing. | Common Stock On May 8, 2015, the Company obtained stockholder consent for the approval of an amendment to our certificate of incorporation to effect a reverse stock split of the Companys common stock at a ratio to be determined by the Board prior to the effective time of the amendment (the Effective Time) of not less than one-for-fifty and not more than one-for-two hundred fifty and the approval of an amendment to our certificate of incorporation to set the number of authorized shares of common stock the Company shall authority to issue following the reverse stock split in an amount to be determined by the Board prior to the Effective Time. The Company filed the amended certificate of incorporation with the State of Delaware on December 16, 2015. The Company effected a reverse stock split of the Companys common stock at a ratio of one-for-two hundred fifty and set the number of authorized shares of common stock the Company shall have authority to issue following the reverse stock split in an amount of 150,000,000. The effect of the reverse stock split has been reflected retroactively for all disclosures. Stock Issuances In January 2015, the Company agreed to issue 39,657 shares of common stock as a price protection to a note holder that originally converted notes at a price of $2.50 and continues to hold these shares. These additional shares would have been issued if the conversion shares price was $1.75. As of December 31, 2015, 33,142 shares of common stock have been issued and $247,000 of interest expense was recorded for this issuance. Preferred Stock The 96,230 shares of Series C preferred stock are convertible into 111 shares of the Company's common stock at the option of the holders at any time. The conversion ratio is based on the average closing bid price of the common stock for the fifteen consecutive trading days ending on the date immediately preceding the date notice of conversion is given, but cannot be less than .20 or more than .2889 common shares for each Series C preferred share. The conversion ratio may be adjusted under certain circumstances such as stock splits or stock dividends. The Company has the right to automatically convert the Series C preferred stock into common stock if the Company lists its shares of common stock on the Nasdaq National Market and the average closing bid price of the Company's common stock on the Nasdaq National Market for 15 consecutive trading days exceeds $3,000.00. Each share of Series C preferred stock is entitled to the number of votes equal to .26 divided by the average closing bid price of the Company's common stock during the fifteen consecutive trading days immediately prior to the date such shares of Series C preferred stock were purchased. In the event of liquidation, the holders of the Series C preferred stock shall participate on an equal basis with the holders of the common stock (as if the Series C preferred stock had converted into common stock) in any distribution of any of the assets or surplus funds of the Company. The holders of Series C preferred stock are entitled to noncumulative dividends if and when declared by the Company's board of directors. No dividends to Series C preferred stockholders were issued or unpaid through December 31, 2015. On December 4, 2008, the Company entered into and closed an Agreement (the Bristol Agreement) with Bristol Investment Fund, Ltd. pursuant to which Bristol agreed to cancel the debt payable by the Company to Bristol in the amount of approximately $20,000 in consideration of the Company issuing Bristol 25,000 shares of Series G Convertible Preferred Stock, which such shares carry a stated value equal to $1.00 per share (the Series G Stock). The Series G Stock is convertible, at any time at the option of the holder, into common shares of the Company based on a conversion price equal to the lesser of $2.50 or 60% of the average of the three lowest trading prices occurring at any time during the 20 trading days preceding the conversion. The Series G Stock, as amended, shall have voting rights on an as converted basis multiplied by 100. In the event of any liquidation or winding up of the Company, the holders of Series G Stock will be entitled to receive, in preference to holders of common stock, an amount equal to the stated value plus interest of 15% per year. The Series G Stock restricts the ability of the holder to convert the Series G Stock and receive shares of the Companys common stock such that the number of shares of the Company common stock held by Bristol and its affiliates after such conversion does not exceed 4.9% of the Companys then issued and outstanding shares of common stock. The Series G Stock was previously referred to in an 8-K filed by the Company on December 10, 2008 in error as the Series E Stock. Further, the Series G Stock initially incorrectly provided that it voted on an as converted basis multiplied by 10. This incorrectly reflected the intent of the Company and the holder. On October 13, 2009 the Company was informed by Theorem Group, LLC that it had purchased all of the outstanding Series G Preferred Stock and Theorem gave notice to the Company that it intended to exercise its ability to vote on all shareholder matters utilizing the super voting privileges provided by the Series G Stock. Effective February 10, 2010, the Company issued 25,000 shares of its new Series H Convertible Preferred Stock (the Series H Preferred) to Theorem Group, LLC, a California limited liability company (the Stockholder), in exchange for the 25,000 shares of Series G Stock then owned by the Stockholder. The foregoing exchange was effected pursuant to that certain Exchange Agreement, dated February 10, 2010, between the Company and the Stockholder (the Exchange Agreement). The Certificate of Designation of the Series H Preferred is based on, and substantially similar to the form and substance of the Certificate of Designation of the Series G Preferred. Some of the corrections, changes and differences between the Certificate of Designation of the Series G Preferred and the Certificate of Designation of the Series H Preferred include the following: · As previously disclosed, the holder of the Series H Preferred is entitled to vote with the common stock, and is entitled to a number of votes equal to (i) the number of shares of common stock it can convert into (without any restrictions or limitations on such conversion), (ii) multiplied by 100. · The holder of the Series H Preferred cannot convert such preferred stock into shares of common stock if the holder and its affiliates after such conversion would own more than 9.9% of the Companys then issued and outstanding shares of common stock. · The Series G Preferred contained a limitation that the holder of the Series G Preferred could not convert such preferred shares into more than 19.999% of the issued and outstanding shares of common stock without the approval of the stockholders if the rules of the principal market on which the common stock is traded would prohibit such a conversion. Since the rules of the Companys principal market did not require such a limitation, that provision has been deleted. On November 8, 2010, Gemini Pharmaceuticals purchased 1,666,667 shares of the Companys Series I Preferred Stock, $.001 par value, at a price of $0.15 per share ($250,000). As the holder of the Series I Preferred Stock, Gemini Pharmaceuticals will be entitled to receive, out of funds legally available, dividends in cash at the annual rate of 8.0% of the Preference Amount ($0.15), when, as, and if declared by the Board. No dividends or other distributions shall be made with respect to any shares of junior stock until dividends in the same amount per share on the Series I Preferred Stock shall have been declared and paid or set apart during that fiscal year. Dividends on the Series I Preferred Stock shall not be cumulative and no right shall accrue to the Series I Preferred Stock by reason of the fact that the Company may fail to declare or pay dividends on the Series I Preferred Stock in the amount of the Dividend Rate per share or in any amount in any previous fiscal year of the Company, whether or not the earnings of the Company in that previous fiscal year were sufficient to pay such dividends in whole or in part. Each share of Series I Preferred Stock shall entitle the holder thereof to such number of votes per share as shall equal the number of shares of Common Stock (rounded to the nearest whole number) into which such share of Series I Preferred Stock is then convertible. Upon any liquidation of the Company, subject to the rights of any series of Preferred Stock that may from time to time come into existence, before any distribution or payment shall be made to the holders of any Junior Stock, the holders of the shares of Series I Preferred Stock then outstanding shall be entitled to receive and be paid out of the assets of the Company legally available for distribution to its stockholders liquidating distributions in cash or property at its fair market value as determined by the Board in the amount of $0.15 per share (as adjusted for any stock dividends, combinations or splits with respect to such shares). Shares of Series I Preferred Stock may, at the option of the holder thereof, be converted at any time or from time to time into fully paid and non-assessable shares of Common Stock. The number of shares of Common Stock which a holder of shares of Series I Preferred Stock shall be entitled to receive upon conversion of such shares shall be the product obtained by multiplying the Conversion Rate by the number of shares of Series I Preferred Stock being converted. Initially, the Series I Preferred Stock is convertible into 6,667 shares of common stock. In the event that the per-share Market Price of the Common Stock over a period of 20 consecutive trading days is equal to at least 130% of the initial conversion price (130% of $0.15), all outstanding shares of Series I Preferred Stock shall be converted automatically into the number of shares of Common Stock into which such shares of Series I Preferred Stock are then convertible without any further action by the holders of such shares and whether or not the certificates representing such shares of Series I Preferred Stock are surrendered to the Company or its transfer agent. Common Stock Warrants Warrant transactions for the years ended December 31, 2015 and 2014 are as follows: Number of Warrants Weighted Average Exercise Price Outstanding, December 31, 2013: 2,364,183 $ 5.00 Granted 1,325,155 3.25 Forfeited (1,037,240 ) 2.50 Exercised - Outstanding at December 31, 2014: 2,652,098 $ 2.50 Granted 9,874,823 1.25 Forfeited (1,200 ) 30.00 Exercised - Outstanding at December 31, 2015 12,525,721 $ 1.25 Exercisable warrants: December 31, 2014 2,652,098 $ 2.50 December 31, 2015 12,525,721 $ 1.25 Consulting Agreements On December 29, 2014, the Company issued 120,000 warrants to a consultant for services rendered. The warrants were valued at $601,000 and were recorded as an expense in the Statement of Operations for the year ended December 31, 2014. On October 1, 2015, the Company issued 120,000 warrants to a consultant for services rendered. The warrants were valued at $448,000 and were recorded as an expense in the Statement of Operations for the year ended December 31, 2015. Stock Options The Company reserved 400,000 shares of its common stock at December 31, 2014 for issuance under the 2014 Stock Incentive Plan (the 2014 Plan). The 2014 Plan, approval by stockholders in May 2015, permits the Company to grant stock options to acquire shares of the Company's common stock, award stock bonuses of the Company's common stock, and grant stock appreciation rights. At December 31, 2015, 133,445 shares of common stock were available for grant and options to purchase 266,555 shares of common stock are outstanding under the 2014 Plan. The Company has no shares of its common stock at December 31, 2015 to issue under the 2010 Stock Incentive Plan (the 2010 Plan). The 2010 Plan, approved by stockholders at the 2011 annual meeting, permits the Company to grant stock options to acquire shares of the Company's common stock, award stock bonuses of the Company's common stock, and grant stock appreciation rights. At December 31, 2015, options to purchase 600 shares of common stock are outstanding under the 2010 Plan. The Company has no shares of its common stock reserved at December 31, 2014 for issuance under the 2003 Stock Incentive Plan (the 2003 Plan). The 2003 Plan, approved by stockholders at the 2003 annual meeting, permits the Company to grant stock options to acquire shares of the Company's common stock, award stock bonuses of the Company's common stock, and grant stock appreciation rights. At December 31, 2015, options to purchase 967 shares of common stock are outstanding under the 2003 Plan. In addition, the Company has reserved 2,000 shares of its common stock for issuance outside of its stock incentive plans. At December 31, 2015, options to purchase 2,000 shares of common stock are outstanding outside of its stock incentive plans. The following table summarizes stock option transactions for the years ended December 31, 2015 and 2014: Number of Options Weighted Average Exercise Price Outstanding, December 31, 2013 117,110 $ 15.00 Granted 321,833 5.00 Exercised - Expired (112,903 ) 22.50 Outstanding, December 31, 2014 326,040 $ 15.00 Granted 52,000 3.29 Exercised - Expired (3,240 ) 61.00 Outstanding, December 31, 2015 374,800 $ 4.88 Exercisable Options: December 31, 2014 111,485 $ 15.00 December 31, 2015 270,762 $ 4.88 The weighted-average fair value of options granted was $1,829,000 and $1,609,000 in 2015 and 2014, respectively. The following table summarizes information about all outstanding and exercisable stock options at December 31, 2015: Outstanding Options Exercisable Options Range of Exercise Prices Number of Options Weighted-Average Remaining Contractual Life Weighted-Average Exercise Price Number of Options Weighted-Average Exercise Price $ 2.50 to $7.50 373,833 3.34 $ 4.76 266,555 $ 3.66 $ 7.51 to $50.00 908 .85 50.00 908 50.00 $ 50.01 to $67.50 59 .71 65.54 59 62.54 374,800 267,522 |
Note 4a - Stock Options and War
Note 4a - Stock Options and Warrants | 6 Months Ended |
Jun. 30, 2016 | |
Guarantees [Abstract] | |
Note 4 - Stock Options and Warrants | Stock Options Following is a summary of the stock option activity: Options Outstanding Weighted Average Exercise Price Outstanding as of December 31, 2015 374,800 $ 4.88 Granted - - Forfeited - - Exercised - - Outstanding as of June 30, 2016 374,800 $ 4.88 Warrants Following is a summary of the warrant activity: Warrants Outstanding Weighted Average Exercise Price Outstanding as of December 31, 2015 12,525,721 $ 1.25 Granted 4,146,162 1.25 Forfeited (339,932 ) 1.25 Exercised (12,610,183 ) 1.25 Outstanding as of June 30, 2016 3,721,768 $ 1.25 |
Note 5 - Income Taxes
Note 5 - Income Taxes | 12 Months Ended |
Dec. 31, 2015 | |
Income Tax Disclosure [Abstract] | |
Note 5 - Income Taxes | Deferred Taxes Deferred taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, and operating losses and tax credit carryforwards. The significant components of net deferred income tax assets for the Company are: December 31, 2015 2014 Deferred tax assets: Federal net operating loss carryforward $ 15,400,000 $ 14,481,000 Other 1,028,000 871,000 Patent amortization (13,000 ) (15,000 ) Deferred tax assets before valuation 16,415,000 15,337,000 Valuation allowance (16,415,000 ) (15,337,000 )) Net deferred income tax assets $ $ Generally accepted accounting principles requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is more likely than not. Realization of the future tax benefits is dependent on the Company's ability to generate sufficient taxable income within the carryforward period. Because of the Company's history of operating losses, management has provided a valuation allowance equal to its net deferred tax assets. The valuation allowance increased by $1,078,000 during the year ended December 31, 2015. Tax Carryforward At December 31, 2015, the Company had net operating loss carryforwards of approximately $35,800,000 to reduce United States federal taxable income in future years. These carryforwards expire through 2035. The Company is no longer subject to U.S. and state tax examinations for years ending before the fiscal year ended December 31, 2011. Management does not believe there will be any material changes in our unrecognized tax positions over the next twelve months. The Company's policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. There was no accrued interest or penalties associated with any unrecognized tax benefits, nor was any interest expense recognized during the years ended December 31, 2015 and 2014. |
Note 6 - Subsequent Events
Note 6 - Subsequent Events | 6 Months Ended | 12 Months Ended |
Jun. 30, 2016 | Dec. 31, 2015 | |
Subsequent Events [Abstract] | ||
Note 6 - Subsequent Events | In July 2016, the Company entered into a securities purchase agreement with one accredited investor to sell 10% convertible debentures, with and an exercise price of $0.40, with an initial principal balance of $112,135 and warrants to acquire up to 280,338 shares of the Companys common stock at an exercise price of $0.45 per share. In July 2016, the Company also issued an Section 4(2) of the Act since the shares were also issued to persons closely associated with the Company and there was no public offering of the shares. On July 15, 2015, the Company entered into a settlement agreement with one noteholder. In accordance with a 10% Convertible Debenture Due July 24, 2016, The Company was required pay accrued interest in case upon a conversion of the debt within three business days for the conversion which did not occur. As compensation for the default, the Company issued allonges to the noteholders for a total of $40,000, increasing the principal amount of the convertible notes. In August 2016, the Company issued 1 In August 2016, the Company entered into a securities purchase agreement with one accredited investor to sell 10% convertible debentures up $1,000,000, with and an exercise price of $0.40, with an initial principal balance of $250,000 and warrants to acquire up to 2,500,000 shares of the Companys common stock at an exercise price of $0.45 per share. | In January 2016, the Company entered into a securities purchase agreement with one accredited investor to sell 10% convertible debentures, with and an exercise price of $1.25, with an initial principal balance of $100,000 and warrants to acquire up to 80,000 shares of the Companys common stock at an exercise price of $1.25 per share. Restructuring Agreements Effective January 8, 2016, Company entered into agreements to effect the restructuring (the Restructuring) of certain unregistered debt and equity securities of the Company that will result in an issuance of up to 28,389,193 shares of common stock of the Company (the Common Stock). In connection with the Restructuring, the Company entered into a note conversion agreement (the Conversion Agreement), a warrant exercise agreement (the Exercise Agreement) and a preferred stock exchange agreement (the Exchange Agreement and, collectively with the Conversion Agreement and the Exercise Agreement, the Restructuring Agreements), pursuant to which the Company and certain of the Companys creditors and investors have agreed that (i) certain outstanding debt of the Company (collectively, the Debt) will be converted into shares of Common Stock; (ii) certain outstanding warrants to purchase shares of capital stock of the Company (collectively, the Warrants) will be exercised on a cashless basis for shares of Common Stock; and (iii) certain outstanding shares of Series H Convertible Preferred Stock of the Company (the Series H Preferred Stock) and Series I Convertible Preferred Stock of the Company (the Series I Preferred Stock and together with the Series H Preferred Stock, the Preferred Stock) will be exchanged for shares of Common Stock. The Conversion Agreement, Exercise Agreement and Exchange Agreement and the transactions contemplated thereby are described in further detail below. Under the Conversion Agreement, certain creditors of the Company holding an aggregate of approximately $15,056,000 (including accrued interest and penalties) of outstanding Debt have agreed to convert all such outstanding Debt into shares of Common Stock at a conversion price of $1.25 per share upon successful completion by the Company of a $6 million financing. In addition, under the Exercise Agreement, certain investors together holding warrants to purchase 12,269,240 shares of capital stock of the Company exchanged such warrants and received one share of Common Stock in exchange for each share of capital stock of the Company underlying the warrants. Finally, under the Exchange Agreement, certain investors together holding 25,000 shares of Series H Preferred Stock and 1,666,667 shares of Series I Preferred Stock have agreed to convert all such shares of Preferred Stock into an aggregate of 4,075,000 shares of Common Stock upon successful completion by the Company of a $6 million financing. The Restructuring Agreements terminated the notes, the warrants, and any anti-dilution protection thereunder. In addition, all creditor and investor parties to the Restructuring Agreements provided a waiver of any and all past defaults and breaches under the Notes, Warrants and Preferred Stock, in consideration of the shares issued pursuant to the Restructuring Agreements. Common Stock The Company has issued an aggregate of 12,397,040 shares of common stock to a total of 29 persons or entities in exchange of the cancellation of warrants on a cashless basis. The shares issued were exempt from the registration requirements of Section 5 of the Securities Act of 1933 (the Act) pursuant to Section 4(2) of the Act since the shares were issued to persons or entities closely associated with the Company and there was no public offering of the shares. The Company also issued an aggregate of 2,283,840 shares of common stock to a total of 15 persons as payment for consulting services provided to the Company. The average valuation of these shares was $2.50 per share. These shares were also exempt from the registration requirements of Section 5 of the Act pursuant to Section 4(2) of the Act since the shares were also issued to persons closely associated with the Company and there was no public offering of the shares. The Company also issued an aggregate of 4,612,341 shares of common stock to two executive officers of the Company in fulfilment of contractual rights held by the officers pursuant to their employment agreements. These shares were also exempt from the registration requirements of Section 5 of the Act pursuant to Section 4(2) of the Act since the shares were also issued to persons closely associated with the Company and there was no public offering of the shares. |
Note 1 - The Company and Summ14
Note 1 - The Company and Summary of Significant Accounting Policies (Policies) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2016 | Dec. 31, 2015 | |
Company And Summary Of Significant Accounting Policies Policies | ||
Basis of Presentation | The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP) and the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Certain information and disclosures required by U.S. GAAP for complete consolidated financial statements have been condensed or omitted herein. The interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Form 10-K for the year ended December 31, 2015. The unaudited interim condensed consolidated financial information presented herein reflects all normal adjustments that are, in the opinion of management, necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. The Company is responsible for the unaudited interim consolidated financial statements included in this report. The results of operations of any interim period are not necessarily indicative of the results for the full year. | |
Going Concern | As shown in the accompanying consolidated financial statements, the Company has incurred an accumulated deficit of $118,190,000 through June 30, 2016. On a consolidated basis, the Company had cash and cash equivalents of $355,000 at June 30, 2016. The Company's plan is to raise additional capital until such time that the Company generates sufficient revenues to cover its cash flow needs and/or it achieves profitability. However, the Company cannot assure that it will accomplish this task and there are many factors that may prevent the Company from reaching its goal of profitability. The current rate of cash usage raises substantial doubt about the Companys ability to continue as a going concern, absent any sources of significant cash flows. In an effort to mitigate this near-term concern the Company intends to seek additional equity or debt financing to obtain sufficient funds to sustain operations. However, the Company cannot provide assurance that it will successfully obtain equity or debt or other financing, if any, sufficient to finance its goals or that the Company will generate future product related revenues. The Companys financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue in existence. | As shown in the accompanying consolidated financial statements, the Company has incurred an accumulated deficit of $145,682,000 through December 31, 2015. On a consolidated basis, the Company had cash and cash equivalents of $47,000 at December 31, 2015. The Company's plan is to raise additional capital until such time that the Company generates sufficient revenues to cover its cash flow needs and/or it achieves profitability. However, the Company cannot assure that it will accomplish this task and there are many factors that may prevent the Company from reaching its goal of profitability. The current rate of cash usage raises substantial doubt about the Companys ability to continue as a going concern, absent any sources of significant cash flows. In an effort to mitigate this near-term concern the Company intends to seek additional equity or debt financing to obtain sufficient funds to sustain operations. The Company plans to increase revenues by introducing new nutraceutical products primarily based on its ergothioneine assets. However, the Company cannot provide assurance that it will successfully obtain equity or debt or other financing, if any, sufficient to finance its goals or that the Company will generate future product related revenues. The Companys financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue in existence. |
Accounts receivable | The Company carries its accounts receivable at cost less an allowance for doubtful accounts. On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance for doubtful accounts, based on a history of past write-offs and collections and current credit conditions. | |
Advertising and Promotional Fees | Advertising expenses consist primarily of costs incurred in the design, development, and printing of Company literature and marketing materials. The Company expenses all advertising expenditures as incurred. There were no advertising expenses for the years ended December 31, 2015 and 2014, respectively. | |
Basis of Consolidation and Comprehensive Income | The accompanying consolidated financial statements include the accounts of OXIS International, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated. The Company's financial statements are prepared using the accrual method of accounting. | The accompanying consolidated financial statements include the accounts of OXIS International, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated. The Company's financial statements are prepared using the accrual method of accounting. |
Cash and Cash Equivalents | The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. | The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. |
Concentrations of Credit Risk | The Company's cash and cash equivalents, marketable securities and accounts receivable are monitored for exposure to concentrations of credit risk. The Company maintains substantially all of its cash balances in a limited number of financial institutions. The balances are each insured by the Federal Deposit Insurance Corporation up to $250,000. The Company does not have balances in excess of this limit at June 30, 2016. | The Company's cash and cash equivalents, marketable securities and accounts receivable are monitored for exposure to concentrations of credit risk. The Company maintains substantially all of its cash balances in a limited number of financial institutions. The balances are each insured by the Federal Deposit Insurance Corporation up to $250,000. The Company does not have balances in excess of this limit at December 31, 2015. |
Fair Value of Financial Instruments | The carrying amounts of cash and cash equivalents, restricted cash, accounts receivable, inventory, accounts payable and accrued expenses approximate fair value because of the short-term nature of these instruments. The fair value of debt is based upon current interest rates for debt instruments with comparable maturities and characteristics and approximates the carrying amount. | The carrying amounts of cash and cash equivalents, restricted cash, accounts receivable, inventory, accounts payable and accrued expenses approximate fair value because of the short-term nature of these instruments. The fair value of debt is based upon current interest rates for debt instruments with comparable maturities and characteristics and approximates the carrying amount. |
Stock Based Compensation to Employees | The Company accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance with ASC 718. Costs are measured at the estimated fair market value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably determinable. The value of equity instruments issued for consideration other than employee services is determined on the earlier of a performance commitment or completion of performance by the provider of goods or services. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized over the term of the consulting agreement. | The Company accounts for its stock-based compensation for employees in accordance with Accounting Standards Codification (ASC) 718. The Company recognizes in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees and non-employees over the related vesting period. The Company granted stock options to purchase 52,000 and 321,833 shares of the Companys common stock to employees and directors during the year ended December 31, 2015 and 2014, respectively. The fair values of employee stock options are estimated for the calculation of the pro forma adjustments at the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions during 2015: expected volatility of 90%; average risk-free interest rate of 1.50% initial expected life of 5 years; no expected dividend yield; and amortized over the vesting period of typically one to four years. The Company reported an expense for share-based compensation for its employees and directors of $221,000 and $162,000 for the year ended December 31, 2015 and 2014, respectively. |
Impairment of Long Lived Assets | The Company's long-lived assets currently consist of capitalized patents. The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. If any of the Company's long-lived assets are considered to be impaired, the amount of impairment to be recognized is equal to the excess of the carrying amount of the assets over the fair value of the assets. | The Company's long-lived assets currently consist of capitalized patents The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. If any of the Company's long-lived assets are considered to be impaired, the amount of impairment to be recognized is equal to the excess of the carrying amount of the assets over the fair value of the assets. |
Income Taxes | The Company accounts for income taxes using the asset and liability approach, whereby deferred income tax assets and liabilities are recognized for the estimated future tax effects, based on current enacted tax laws, of temporary differences between financial and tax reporting for current and prior periods. Deferred tax assets are reduced, if necessary, by a valuation allowance if the corresponding future tax benefits may not be realized. | The Company accounts for income taxes using the asset and liability approach, whereby deferred income tax assets and liabilities are recognized for the estimated future tax effects, based on current enacted tax laws, of temporary differences between financial and tax reporting for current and prior periods. Deferred tax assets are reduced, if necessary, by a valuation allowance if the corresponding future tax benefits may not be realized. |
Net Income (Loss) per Share | Basic net income (loss) per share is computed by dividing the net loss for the period by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing the net loss for the period by the weighted average number of common shares outstanding during the period, plus the potential dilutive effect of common shares issuable upon exercise or conversion of outstanding stock options and warrants during the period. The weighted average number of potentially dilutive common shares excluded from the calculation of net income (loss) per share totaled in 12,900,521 and 1,677,144 as of June 30, 2016 and 2015, respectively. | Basic net income (loss) per share is computed by dividing the net loss for the period by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing the net loss for the period by the weighted average number of common shares outstanding during the period, plus the potential dilutive effect of common shares issuable upon exercise or conversion of outstanding stock options and warrants during the period. The weighted average number of potentially dilutive common shares excluded from the calculation of net income (loss) per share totaled in 12,525,721 in 2015 and 3,092,737 in 2014. |
Patents | Acquired patents are capitalized at their acquisition cost or fair value. The legal costs, patent registration fees and models and drawings required for filing patent applications are capitalized if they relate to commercially viable technologies. Commercially viable technologies are those technologies that are projected to generate future positive cash flows in the near term. Legal costs associated with patent applications that are not determined to be commercially viable are expensed as incurred. All research and development costs incurred in developing the patentable idea are expensed as incurred. Legal fees from the costs incurred in successful defense to the extent of an evident increase in the value of the patents are capitalized. Capitalized cost for pending patents are amortized on a straight-line basis over the remaining twenty year legal life of each patent after the costs have been incurred. Once each patent is issued, capitalized costs are amortized on a straight-line basis over the shorter of the patent's remaining statutory life, estimated economic life or ten years. | Acquired patents are capitalized at their acquisition cost or fair value. The legal costs, patent registration fees and models and drawings required for filing patent applications are capitalized if they relate to commercially viable technologies. Commercially viable technologies are those technologies that are projected to generate future positive cash flows in the near term. Legal costs associated with patent applications that are not determined to be commercially viable are expensed as incurred. All research and development costs incurred in developing the patentable idea are expensed as incurred. Legal fees from the costs incurred in successful defense to the extent of an evident increase in the value of the patents are capitalized. Capitalized cost for pending patents are amortized on a straight-line basis over the remaining twenty year legal life of each patent after the costs have been incurred. Once each patent is issued, capitalized costs are amortized on a straight-line basis over the shorter of the patent's remaining statutory life, estimated economic life or ten years. |
Fixed Assets | Fixed assets are stated at cost. Depreciation is computed on a straight-line basis over the estimated useful lives of the assets, which are 3 to 10 years for machinery and equipment and the shorter of the lease term or estimated economic life for leasehold improvements. | Fixed assets is stated at cost. Depreciation is computed on a straight-line basis over the estimated useful lives of the assets, which are 3 to 10 years for machinery and equipment and the shorter of the lease term or estimated economic life for leasehold improvements. |
Fair Value | The carrying amounts reported in the balance sheets for receivables and current liabilities each qualify as financial instruments and are a reasonable estimate of fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest. The three levels are defined as follows: ● Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. The Companys Level 1 assets include cash equivalents, primarily institutional money market funds, whose carrying value represents fair value because of their short-term maturities of the investments held by these funds. ● Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. The Companys Level 2 liabilities consist of liabilities arising from the issuance of convertible securities and in accordance with ASC 815-40: a warrant liability for detachable warrants, as well as an accrued derivative liability for the beneficial conversion feature. These liabilities are remeasured each reporting period. Fair value is determined using the Black-Scholes valuation model based on observable market inputs, such as share price data and a discount rate consistent with that of a government-issued security of a similar maturity. ● Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement. The following table represents the Companys assets and liabilities by level measured at fair value on a recurring basis at June 30, 2016. Description Level 1 Level 2 Level 3 Assets $ $ $ Liabilities Warrant liability 492,000 | The carrying amounts reported in the balance sheets for receivables and current liabilities each qualify as financial instruments and are a reasonable estimate of fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest. The three levels are defined as follows: · Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. The Companys Level 1 assets include cash equivalents, primarily institutional money market funds, whose carrying value represents fair value because of their short-term maturities of the investments held by these funds. · Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. The Companys Level 2 liabilities consist of liabilities arising from the issuance of convertible securities and in accordance with ASC 815-40: a warrant liability for detachable warrants, as well as an accrued derivative liability for the beneficial conversion feature. These liabilities are remeasured each reporting period. Fair value is determined using the Black-Scholes valuation model based on observable market inputs, such as share price data and a discount rate consistent with that of a government-issued security of a similar maturity. · Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement. The following table represents the Companys assets and liabilities by level measured at fair value on a recurring basis at December 31, 2015. Description Level 1 Level 2 Level 3 Assets $ $ $ Liabilities Warrant liability 44,531,000 Accrued expense 4,326,000 |
Research and Development | Research and development costs are expensed as incurred and reported as research and development expense. Research and development costs totaling $475,000 and $250,000 for the six months ended June 30, 2016 and 2015, respectively. | Research and development costs are expensed as incurred and reported as research and development expense. Research and development costs totaling $1,000,000 and $-0- for the years ended December 31, 2015 and 2014, respectively. |
Revenue Recognition | License Revenue License arrangements may consist of non-refundable upfront license fees, exclusive licensed rights to patented or patent pending technology, and various performance or sales milestones and future product royalty payments. Some of these arrangements are multiple element arrangements. Non-refundable, up-front fees that are not contingent on any future performance by us, and require no consequential continuing involvement on our part, are recognized as revenue when the license term commences and the licensed data, technology and/or compound is delivered. We defer recognition of non-refundable upfront fees if we have continuing performance obligations without which the technology, right, product or service conveyed in conjunction with the non-refundable fee has no utility to the licensee that is separate and independent of our performance under the other elements of the arrangement. In addition, if we have continuing involvement through research and development services that are required because our know-how and expertise related to the technology is proprietary to us, or can only be performed by us, then such up-front fees are deferred and recognized over the period of continuing involvement. Payments related to substantive, performance-based milestones in a research and development arrangement are recognized as revenue upon the achievement of the milestones as specified in the underlying agreements when they represent the culmination of the earnings process. | Product Revenue The Company manufactures, or has manufactured on a contract basis, fine chemicals and nutraceutical products, which are its primary products to be sold to customers. Revenue from the sale of its products, including shipping fees, will be recognized when title to the products is transferred to the customer which usually occurs upon shipment or delivery, depending upon the terms of the sales order and when collectability is reasonably assured. Revenue from sales to distributors of its products will be recognized, net of allowances, upon delivery of product to the distributors. According to the terms of individual distributor contracts, a distributor may return product up to a maximum amount and under certain conditions contained in its contract. Allowances are calculated based upon historical data, current economic conditions and the underlying contractual terms. License Revenue License arrangements may consist of non-refundable upfront license fees, exclusive licensed rights to patented or patent pending technology, and various performance or sales milestones and future product royalty payments. Some of these arrangements are multiple element arrangements. Non-refundable, up-front fees that are not contingent on any future performance by us, and require no consequential continuing involvement on our part, are recognized as revenue when the license term commences and the licensed data, technology and/or compound is delivered. We defer recognition of non-refundable upfront fees if we have continuing performance obligations without which the technology, right, product or service conveyed in conjunction with the non-refundable fee has no utility to the licensee that is separate and independent of our performance under the other elements of the arrangement. In addition, if we have continuing involvement through research and development services that are required because our know-how and expertise related to the technology is proprietary to us, or can only be performed by us, then such up-front fees are deferred and recognized over the period of continuing involvement. Payments related to substantive, performance-based milestones in a research and development arrangement are recognized as revenue upon the achievement of the milestones as specified in the underlying agreements when they represent the culmination of the earnings process. |
Use of Estimates | The financial statements and notes are representations of the Company's management, which is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities revenues and expenses and disclosures of contingent assets and liabilities at the date of the financial statements. Actual results could differ from those estimates. | The financial statements and notes are representations of the Company's management, which is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities revenues and expenses and disclosures of contingent assets and liabilities at the date of the financial statements. Actual results could differ from those estimates. |
Note 1 - The Company and Summ15
Note 1 - The Company and Summary of Significant Accounting Policies (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2016 | Dec. 31, 2015 | |
Company And Summary Of Significant Accounting Policies Tables | ||
Company assets and liabilities by level measured at fair value on a recurring basis | Description Level 1 Level 2 Level 3 Assets $ $ $ Liabilities Warrant liability 492,000 | Description Level 1 Level 2 Level 3 Assets $ $ $ Liabilities Warrant liability 44,531,000 Accrued expense 4,326,000 |
Note 2 - Patents (Tables)
Note 2 - Patents (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Patents Tables | |
Patents | December 31, 2015 December 31, 2014 Capitalized patent costs $ 642,000 $ 642,000 Accumulated amortization (642,000 ) (642,000 ) $ - $ - |
Note 4 - Stockholders' Equity (
Note 4 - Stockholders' Equity (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2016 | Dec. 31, 2015 | |
Stock Options And Warrants Tables | ||
Summary of the warrant activity | Warrants Outstanding Weighted Average Exercise Price Outstanding as of December 31, 2015 12,525,721 $ 1.25 Granted 4,146,162 1.25 Forfeited (339,932 ) 1.25 Exercised (12,610,183 ) 1.25 Outstanding as of June 30, 2016 3,721,768 $ 1.25 | Number of Warrants Weighted Average Exercise Price Outstanding, December 31, 2013: 2,364,183 $ 5.00 Granted 1,325,155 3.25 Forfeited (1,037,240 ) 2.50 Exercised - Outstanding at December 31, 2014: 2,652,098 $ 2.50 Granted 9,874,823 1.25 Forfeited (1,200 ) 30.00 Exercised - Outstanding at December 31, 2015 12,525,721 $ 1.25 Exercisable warrants: December 31, 2014 2,652,098 $ 2.50 December 31, 2015 12,525,721 $ 1.25 |
Summary of the stock option activity | Options Outstanding Weighted Average Exercise Price Outstanding as of December 31, 2015 374,800 $ 4.88 Granted - - Forfeited - - Exercised - - Outstanding as of June 30, 2016 374,800 $ 4.88 | Number of Options Weighted Average Exercise Price Outstanding, December 31, 2013 117,110 $ 15.00 Granted 321,833 5.00 Exercised - Expired (112,903 ) 22.50 Outstanding, December 31, 2014 326,040 $ 15.00 Granted 52,000 3.29 Exercised - Expired (3,240 ) 61.00 Outstanding, December 31, 2015 374,800 $ 4.88 Exercisable Options: December 31, 2014 111,485 $ 15.00 December 31, 2015 270,762 $ 4.88 |
Summary of outstanding and exercisable stock options | Outstanding Options Exercisable Options Range of Exercise Prices Number of Options Weighted-Average Remaining Contractual Life Weighted-Average Exercise Price Number of Options Weighted-Average Exercise Price $ 2.50 to $7.50 373,833 3.34 $ 4.76 266,555 $ 3.66 $ 7.51 to $50.00 908 .85 50.00 908 50.00 $ 50.01 to $67.50 59 .71 65.54 59 62.54 374,800 267,522 |
Note 4a - Stock Options and W18
Note 4a - Stock Options and Warrants (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2016 | Dec. 31, 2015 | |
Stock Options And Warrants Tables | ||
Summary of the stock option activity | Options Outstanding Weighted Average Exercise Price Outstanding as of December 31, 2015 374,800 $ 4.88 Granted - - Forfeited - - Exercised - - Outstanding as of June 30, 2016 374,800 $ 4.88 | Number of Options Weighted Average Exercise Price Outstanding, December 31, 2013 117,110 $ 15.00 Granted 321,833 5.00 Exercised - Expired (112,903 ) 22.50 Outstanding, December 31, 2014 326,040 $ 15.00 Granted 52,000 3.29 Exercised - Expired (3,240 ) 61.00 Outstanding, December 31, 2015 374,800 $ 4.88 Exercisable Options: December 31, 2014 111,485 $ 15.00 December 31, 2015 270,762 $ 4.88 |
Summary of the warrant activity | Warrants Outstanding Weighted Average Exercise Price Outstanding as of December 31, 2015 12,525,721 $ 1.25 Granted 4,146,162 1.25 Forfeited (339,932 ) 1.25 Exercised (12,610,183 ) 1.25 Outstanding as of June 30, 2016 3,721,768 $ 1.25 | Number of Warrants Weighted Average Exercise Price Outstanding, December 31, 2013: 2,364,183 $ 5.00 Granted 1,325,155 3.25 Forfeited (1,037,240 ) 2.50 Exercised - Outstanding at December 31, 2014: 2,652,098 $ 2.50 Granted 9,874,823 1.25 Forfeited (1,200 ) 30.00 Exercised - Outstanding at December 31, 2015 12,525,721 $ 1.25 Exercisable warrants: December 31, 2014 2,652,098 $ 2.50 December 31, 2015 12,525,721 $ 1.25 |
Note 5 - Income Taxes (Tables)
Note 5 - Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Income Tax Disclosure [Abstract] | |
Components of net deferred income tax assets | December 31, 2015 2014 Deferred tax assets: Federal net operating loss carryforward $ 15,400,000 $ 14,481,000 Other 1,028,000 871,000 Patent amortization (13,000 ) (15,000 ) Deferred tax assets before valuation 16,415,000 15,337,000 Valuation allowance (16,415,000 ) (15,337,000 )) Net deferred income tax assets $ $ |
Note 1 - The Company and Summ20
Note 1 - The Company and Summary of Significant Accounting Policies (Details) - USD ($) | Jun. 30, 2016 | Dec. 31, 2015 |
Level 1 | ||
Assets | ||
Asset | $ 0 | $ 0 |
Liabilities | ||
Warrant liability | 0 | 0 |
Accrued expense | 0 | |
Level 2 | ||
Assets | ||
Asset | 0 | 0 |
Liabilities | ||
Warrant liability | 492,000 | 44,531,000 |
Accrued expense | 4,326,000 | |
Level 3 | ||
Assets | ||
Asset | 0 | 0 |
Liabilities | ||
Warrant liability | $ 0 | 0 |
Accrued expense | $ 0 |
Note 1 - The Company and Summ21
Note 1 - The Company and Summary of Significant Accounting Policies (Details Narrative) - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||
Jun. 30, 2016 | Jun. 30, 2015 | Jun. 30, 2016 | Jun. 30, 2015 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Accumulated deficit | $ (118,190,000) | $ (118,190,000) | $ (145,682,000) | $ (112,956,000) | $ (89,467,000) | ||
Cash and cash equivalent | 355,000 | $ 125,000 | $ 355,000 | $ 125,000 | $ 47,000 | $ 855,000 | $ 43,000 |
Stock options granted | 52,000 | 321,833 | |||||
Expected volatility | 90.00% | ||||||
Risk free interest rate | 1.50% | ||||||
Expected life | 5 years | ||||||
Expected dividend yield | $ 0 | ||||||
Share based compensation expense | $ 221,000 | $ 162,000 | |||||
Diluted shares excluded from calcuation of EPS | 12,900,521 | 1,677,144 | 12,525,721 | 3,092,737 | |||
Research and development costs | $ 250,000 | $ 0 | $ 475,000 | $ 250,000 | $ 1,000,000 | $ 0 | |
Minimum | |||||||
Amortized over vesting period | 1 year | ||||||
Maximum | |||||||
Amortized over vesting period | 4 years |
Note 2 - Patents (Details)
Note 2 - Patents (Details) - USD ($) | Dec. 31, 2015 | Dec. 31, 2014 |
Patents Details | ||
Capitalized patent costs | $ 642,000 | $ 642,000 |
Accumulated amortization | (642,000) | (642,000) |
Net | $ 0 | $ 0 |
Note 4 - Stockholders' Equity23
Note 4 - Stockholders' Equity (Details) - Warrant - $ / shares | 12 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
Warrants Outstanding | ||
Outstanding, beginning | 2,652,098 | 2,364,183 |
Granted | 9,874,823 | 1,325,155 |
Forfeited | (1,200) | (1,037,240) |
Exercised | 0 | 0 |
Outstanding, ending | 12,525,721 | 2,652,098 |
Exercisable, ending | 12,525,721 | 2,652,098 |
Weighted Average Exercise Price | ||
Outstanding, beginning | $ 2.50 | $ 5 |
Granted | 1.25 | 3.25 |
Forfeited | 30 | 2.50 |
Exercised | 0 | 0 |
Outstanding, ending | 1.25 | 2.50 |
Exercisable, ending | $ 1.25 | $ 2.50 |
Note 4 - Stockholders' Equity24
Note 4 - Stockholders' Equity (Details 1) - Stock Options - $ / shares | 6 Months Ended | 12 Months Ended | |
Jun. 30, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Options Outstanding | |||
Outstanding, beginning | 374,800 | 326,040 | 117,110 |
Granted | 0 | 52,000 | 321,833 |
Exercised | 0 | 0 | 0 |
Expired | 0 | (3,240) | (112,903) |
Outstanding, ending | 374,800 | 374,800 | 326,040 |
Exercisable, ending | 270,762 | 111,485 | |
Weighted Average Exercise Price | |||
Outstanding, beginning | $ 4.88 | $ 15 | $ 15 |
Granted | 0 | 3.29 | 5 |
Exercised | 0 | 0 | 0 |
Expired | 0 | 61 | 22.50 |
Outstanding, ending | $ 4.88 | 4.88 | 15 |
Exercisable, ending | $ 4.88 | $ 15 |
Note 4a - Stock Options and W25
Note 4a - Stock Options and Warrants (Details) - Stock Options - $ / shares | 6 Months Ended | 12 Months Ended | |
Jun. 30, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Options Outstanding | |||
Outstanding, beginning | 374,800 | 326,040 | 117,110 |
Granted | 0 | 52,000 | 321,833 |
Forfeited | 0 | 3,240 | 112,903 |
Exercised | 0 | 0 | 0 |
Outstanding, ending | 374,800 | 374,800 | 326,040 |
Exercisable, ending | 270,762 | 111,485 | |
Weighted Average Exercise Price | |||
Outstanding, beginning | $ 4.88 | $ 15 | $ 15 |
Granted | 0 | 3.29 | 5 |
Forfeited | 0 | 61 | 22.50 |
Exercised | 0 | 0 | 0 |
Outstanding, ending | $ 4.88 | 4.88 | 15 |
Exercisable, ending | $ 4.88 | $ 15 |
Note 4a - Stock Options and W26
Note 4a - Stock Options and Warrants (Details 1) - WarrantMember | 6 Months Ended |
Jun. 30, 2016$ / sharesshares | |
Warrants Outstanding | |
Outstanding, beginning | shares | 12,525,721 |
Granted | shares | 4,146,162 |
Forfeited | shares | (339,932) |
Exercised | shares | (12,610,183) |
Outstanding, ending | shares | 3,721,768 |
Weighted Average Exercise Price | |
Outstanding, beginning | $ / shares | $ 1.25 |
Granted | $ / shares | 1.25 |
Forfeited | $ / shares | 1.25 |
Exercised | $ / shares | 1.25 |
Outstanding, ending | $ / shares | $ 1.25 |
Note 5 - Income Taxes (Details)
Note 5 - Income Taxes (Details) - USD ($) | Dec. 31, 2015 | Dec. 31, 2014 |
Deferred tax assets: | ||
Federal net operating loss carryforward | $ 15,400,000 | $ 14,481,000 |
Other | 1,028,000 | 871,000 |
Patent amortization | (13,000) | (15,000) |
Deferred tax assets before valuation | 16,415,000 | 15,337,000 |
Valuation allowance | (16,415,000) | (15,337,000) |
Net deferred income tax assets | $ 0 | $ 0 |
Note 5 - Income Taxes (Details
Note 5 - Income Taxes (Details Narrative) | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Note 5 - Income Taxes Details Narrative | |
Net operating loss carryforward | $ 35,800,000 |
Net operating loss carryforward, expiration | The operating loss carryforwards expire through 2035. |